WO2021071534A1 - Mutant vaccinia viruses and use thereof - Google Patents
Mutant vaccinia viruses and use thereof Download PDFInfo
- Publication number
- WO2021071534A1 WO2021071534A1 PCT/US2019/065303 US2019065303W WO2021071534A1 WO 2021071534 A1 WO2021071534 A1 WO 2021071534A1 US 2019065303 W US2019065303 W US 2019065303W WO 2021071534 A1 WO2021071534 A1 WO 2021071534A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- virus
- amino acid
- vaccinia virus
- protein
- seq
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title claims abstract description 416
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 134
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 99
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 93
- 210000002845 virion Anatomy 0.000 claims abstract description 93
- 241000700605 Viruses Species 0.000 claims abstract description 78
- 229920001184 polypeptide Polymers 0.000 claims abstract description 70
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 67
- 244000309459 oncolytic virus Species 0.000 claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 37
- 230000024203 complement activation Effects 0.000 claims abstract description 31
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims abstract description 27
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 27
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims abstract description 26
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims abstract description 26
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims abstract description 25
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims abstract description 25
- 229940126546 immune checkpoint molecule Drugs 0.000 claims abstract description 25
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 12
- 230000005860 defense response to virus Effects 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 141
- 101150082093 H3L gene Proteins 0.000 claims description 88
- 101100338297 Vaccinia virus (strain Western Reserve) VACWR101 gene Proteins 0.000 claims description 86
- 102200082900 rs33983205 Human genes 0.000 claims description 86
- 239000000427 antigen Substances 0.000 claims description 85
- 108091007433 antigens Proteins 0.000 claims description 85
- 102000036639 antigens Human genes 0.000 claims description 85
- 101150053466 D8L gene Proteins 0.000 claims description 60
- 102000039446 nucleic acids Human genes 0.000 claims description 59
- 108020004707 nucleic acids Proteins 0.000 claims description 59
- 150000007523 nucleic acids Chemical class 0.000 claims description 59
- 101100165857 Vaccinia virus (strain Ankara) MVA105L gene Proteins 0.000 claims description 58
- 101100165860 Vaccinia virus (strain Western Reserve) VACWR113 gene Proteins 0.000 claims description 58
- 101150080480 A27L gene Proteins 0.000 claims description 50
- 101100268532 Vaccinia virus (strain Western Reserve) VACWR150 gene Proteins 0.000 claims description 48
- 238000006467 substitution reaction Methods 0.000 claims description 48
- 101150020591 L1R gene Proteins 0.000 claims description 41
- 101100181322 Vaccinia virus (strain Ankara) MVA080R gene Proteins 0.000 claims description 39
- 101100342626 Vaccinia virus (strain Western Reserve) VACWR088 gene Proteins 0.000 claims description 39
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 38
- 210000004881 tumor cell Anatomy 0.000 claims description 32
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 31
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 31
- 238000012217 deletion Methods 0.000 claims description 31
- 230000037430 deletion Effects 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 26
- -1 TGIT Proteins 0.000 claims description 23
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 230000004927 fusion Effects 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 19
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 19
- 108010031318 Vitronectin Proteins 0.000 claims description 18
- 125000000539 amino acid group Chemical group 0.000 claims description 18
- 210000002865 immune cell Anatomy 0.000 claims description 18
- 208000034578 Multiple myelomas Diseases 0.000 claims description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 14
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 14
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 14
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 14
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 14
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 14
- 102100030886 Complement receptor type 1 Human genes 0.000 claims description 12
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 claims description 12
- 102100039373 Membrane cofactor protein Human genes 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 12
- 210000004962 mammalian cell Anatomy 0.000 claims description 12
- 238000010361 transduction Methods 0.000 claims description 12
- 230000026683 transduction Effects 0.000 claims description 12
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 11
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 11
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 claims description 11
- 210000002950 fibroblast Anatomy 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 102000016550 Complement Factor H Human genes 0.000 claims description 10
- 108010053085 Complement Factor H Proteins 0.000 claims description 10
- 108091008324 binding proteins Proteins 0.000 claims description 10
- 102000003780 Clusterin Human genes 0.000 claims description 9
- 108090000197 Clusterin Proteins 0.000 claims description 9
- 102100031673 Corneodesmosin Human genes 0.000 claims description 9
- 229940096437 Protein S Drugs 0.000 claims description 9
- 108010079274 Thrombomodulin Proteins 0.000 claims description 9
- 102100035140 Vitronectin Human genes 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 8
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 8
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 8
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 8
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 8
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 8
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 8
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 8
- 102100035721 Syndecan-1 Human genes 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 8
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 8
- 102000046935 human TNFRSF17 Human genes 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 8
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 7
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims description 7
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims description 7
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 7
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 7
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 7
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 7
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims description 7
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims description 7
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 7
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 7
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 7
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 7
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 7
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 claims description 7
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 7
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 7
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 7
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 7
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 7
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 7
- 102100033016 Integrin beta-7 Human genes 0.000 claims description 7
- 102000002698 KIR Receptors Human genes 0.000 claims description 7
- 108010043610 KIR Receptors Proteins 0.000 claims description 7
- 102000017578 LAG3 Human genes 0.000 claims description 7
- 101150030213 Lag3 gene Proteins 0.000 claims description 7
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 7
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 7
- 101150097162 SERPING1 gene Proteins 0.000 claims description 7
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims description 7
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims description 7
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 7
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 7
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 7
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 7
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 7
- 102000048362 human PDCD1 Human genes 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 108010021315 integrin beta7 Proteins 0.000 claims description 7
- 101150013553 CD40 gene Proteins 0.000 claims description 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 6
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 6
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 6
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 6
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 6
- 241000700584 Simplexvirus Species 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 5
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 5
- 241000711975 Vesicular stomatitis virus Species 0.000 claims description 5
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 241000712079 Measles morbillivirus Species 0.000 claims description 4
- 241000702263 Reovirus sp. Species 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 3
- 241000709687 Coxsackievirus Species 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 241001466953 Echovirus Species 0.000 claims description 3
- 241000710831 Flavivirus Species 0.000 claims description 3
- 241001372913 Maraba virus Species 0.000 claims description 3
- 241000700562 Myxoma virus Species 0.000 claims description 3
- 241000709664 Picornaviridae Species 0.000 claims description 3
- 241000125945 Protoparvovirus Species 0.000 claims description 3
- 241000710961 Semliki Forest virus Species 0.000 claims description 3
- 241000837158 Senecavirus A Species 0.000 claims description 3
- 108010065158 Tumor Necrosis Factor Ligand Superfamily Member 14 Proteins 0.000 claims description 3
- 101900219663 Vaccinia virus Cell surface-binding protein Proteins 0.000 claims description 3
- 101900350956 Vaccinia virus Envelope protein H3 Proteins 0.000 claims description 3
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 102000012607 Thrombomodulin Human genes 0.000 claims 3
- 102000023732 binding proteins Human genes 0.000 claims 3
- 102000012883 Tumor Necrosis Factor Ligand Superfamily Member 14 Human genes 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 abstract description 46
- 230000000295 complement effect Effects 0.000 abstract description 33
- 230000035772 mutation Effects 0.000 abstract description 31
- 230000001404 mediated effect Effects 0.000 abstract description 17
- 230000003612 virological effect Effects 0.000 abstract description 17
- 230000008685 targeting Effects 0.000 abstract description 11
- 230000000903 blocking effect Effects 0.000 abstract description 6
- 230000037361 pathway Effects 0.000 abstract description 2
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 131
- 235000018102 proteins Nutrition 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 39
- 230000027455 binding Effects 0.000 description 36
- 210000001744 T-lymphocyte Anatomy 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 32
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 26
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 26
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 24
- 201000000050 myeloid neoplasm Diseases 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 21
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 239000012528 membrane Substances 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000011089 carbon dioxide Nutrition 0.000 description 14
- 238000011282 treatment Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000010530 Virus Neutralization Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 230000029812 viral genome replication Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 8
- 229920002971 Heparan sulfate Polymers 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 108010067390 Viral Proteins Proteins 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000000174 oncolytic effect Effects 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 229920001287 Chondroitin sulfate Polymers 0.000 description 7
- 229940059329 chondroitin sulfate Drugs 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 6
- 101150068740 C21R gene Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102220516341 Obscurin-like protein 1_F17R_mutation Human genes 0.000 description 6
- 102100026966 Thrombomodulin Human genes 0.000 description 6
- 101100502116 Vaccinia virus (strain Copenhagen) F17R gene Proteins 0.000 description 6
- 101100226455 Vaccinia virus (strain Western Reserve) VACWR056 gene Proteins 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 230000006037 cell lysis Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 101710199510 Keratin, type I cuticular Ha3-I Proteins 0.000 description 5
- 102220486286 Mannose-1-phosphate guanyltransferase beta_K33A_mutation Human genes 0.000 description 5
- 102220550092 Matrix metalloproteinase-14_D35A_mutation Human genes 0.000 description 5
- 101150003725 TK gene Proteins 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102220602431 Complement component C6_I14A_mutation Human genes 0.000 description 4
- 102220503972 Endogenous retrovirus group K member 6 Rec protein_R16A_mutation Human genes 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102220476702 Interleukin-1 receptor-associated kinase 3_I156A_mutation Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102220566631 Lipoprotein lipase_D15A_mutation Human genes 0.000 description 4
- 102220465533 Lymphocyte activation gene 3 protein_R137A_mutation Human genes 0.000 description 4
- 102220510411 Matrix-remodeling-associated protein 5_E45A_mutation Human genes 0.000 description 4
- 102220558661 Nuclear protein 1_K38R_mutation Human genes 0.000 description 4
- 102220503331 Polyadenylate-binding protein 2_L136S_mutation Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005206 flow analysis Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 102200080930 rs137852221 Human genes 0.000 description 4
- 102220104984 rs373970237 Human genes 0.000 description 4
- 102220145928 rs886059044 Human genes 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 102220591934 Aquaporin-3_F34A_mutation Human genes 0.000 description 3
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 3
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102000006601 Thymidine Kinase Human genes 0.000 description 3
- 108020004440 Thymidine kinase Proteins 0.000 description 3
- 101800003344 Vaccinia growth factor Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 102220479618 Voltage-dependent L-type calcium channel subunit beta-2_N40A_mutation Human genes 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000004017 serum-free culture medium Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 230000029302 virus maturation Effects 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102220554198 APC membrane recruitment protein 1_E25A_mutation Human genes 0.000 description 2
- 102220554200 APC membrane recruitment protein 1_K27A_mutation Human genes 0.000 description 2
- 101150112145 B16L gene Proteins 0.000 description 2
- 102220614558 Calmodulin-3_N27A_mutation Human genes 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 2
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 102220555447 Delta and Notch-like epidermal growth factor-related receptor_K98A_mutation Human genes 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 102220604084 Homeobox protein SIX3_E40A_mutation Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001050472 Homo sapiens Integral membrane protein 2A Proteins 0.000 description 2
- 102220474346 L-xylulose reductase_R107A_mutation Human genes 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 231100000070 MTS assay Toxicity 0.000 description 2
- 238000000719 MTS assay Methods 0.000 description 2
- 102220595576 Major vault protein_D39A_mutation Human genes 0.000 description 2
- 102220578305 Microtubule-associated proteins 1A/1B light chain 3B_I35A_mutation Human genes 0.000 description 2
- 102220469874 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN_A34D_mutation Human genes 0.000 description 2
- 241000700625 Poxviridae Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102220477327 Protein XRP2_Q31A_mutation Human genes 0.000 description 2
- 102220477328 Protein XRP2_R32A_mutation Human genes 0.000 description 2
- 102220469781 Putative high mobility group protein B1-like 1_Y109A_mutation Human genes 0.000 description 2
- 102220494503 Receptor of activated protein C kinase 1_K127A_mutation Human genes 0.000 description 2
- 102220497244 Serine-tRNA ligase, cytoplasmic_R44A_mutation Human genes 0.000 description 2
- 102220493337 Sodium/calcium exchanger 3_K37A_mutation Human genes 0.000 description 2
- 102220501747 Sodium/calcium exchanger 3_K48A_mutation Human genes 0.000 description 2
- 102220467795 Torsin-1A_K108A_mutation Human genes 0.000 description 2
- 102220468683 Tubulin polyglutamylase TTLL7_K125A_mutation Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102100024586 Tumor necrosis factor ligand superfamily member 14 Human genes 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 102220469588 Voltage-dependent L-type calcium channel subunit beta-2_D60A_mutation Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 239000000367 immunologic factor Substances 0.000 description 2
- 230000034184 interaction with host Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 102200087889 rs1050228 Human genes 0.000 description 2
- 102220253683 rs121913596 Human genes 0.000 description 2
- 102220253319 rs1307934269 Human genes 0.000 description 2
- 102200120415 rs140397694 Human genes 0.000 description 2
- 102220238245 rs1555952639 Human genes 0.000 description 2
- 102220065439 rs370768715 Human genes 0.000 description 2
- 102220103579 rs755210880 Human genes 0.000 description 2
- 102220097502 rs876660844 Human genes 0.000 description 2
- 102220122849 rs886043235 Human genes 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000010066 viral adhesion Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150108168 A33R gene Proteins 0.000 description 1
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102100037332 Aquaporin-3 Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101150083809 D10L gene Proteins 0.000 description 1
- 101150116298 D12L gene Proteins 0.000 description 1
- 101150044623 D13L gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 102220471012 Dual specificity mitogen-activated protein kinase kinase 6_K109A_mutation Human genes 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 101150009495 E10R gene Proteins 0.000 description 1
- 101150040570 E11L gene Proteins 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 102220508088 Endogenous retrovirus group K member 104 Rec protein_R220A_mutation Human genes 0.000 description 1
- 102100038083 Endosialin Human genes 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 239000004230 Fast Yellow AB Substances 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 101150111468 H3 gene Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101000829725 Homo sapiens Phospholipid hydroperoxide glutathione peroxidase Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001056234 Homo sapiens Sperm mitochondrial-associated cysteine-rich protein Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- 102220631528 Krueppel-like factor 13_G55W_mutation Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 108090000015 Mesothelin Proteins 0.000 description 1
- 102000003735 Mesothelin Human genes 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102220483672 Microtubule-associated protein 2_L196S_mutation Human genes 0.000 description 1
- 101710164418 Movement protein TGB2 Proteins 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 101710173867 NADH-cytochrome b5 reductase 3 Proteins 0.000 description 1
- 101150073111 NPH1 gene Proteins 0.000 description 1
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 description 1
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 102220465902 Phosphatidylcholine-sterol acyltransferase_S177A_mutation Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102220485743 Protein CIP2A_K117A_mutation Human genes 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102220532925 Putative speedy protein-like protein 3_F199A_mutation Human genes 0.000 description 1
- 102100025873 RNA-binding protein 27 Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 239000004231 Riboflavin-5-Sodium Phosphate Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100021225 Serine hydroxymethyltransferase, cytosolic Human genes 0.000 description 1
- 102220486896 Short transient receptor potential channel 1_R154A_mutation Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108010045306 T134 peptide Proteins 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 102100038126 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 1
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 1
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 101150025207 VPK2 gene Proteins 0.000 description 1
- 101100171542 Vaccinia virus (strain Western Reserve) VACWR066 gene Proteins 0.000 description 1
- 101100064540 Vaccinia virus (strain Western Reserve) VACWR067 gene Proteins 0.000 description 1
- 101100076195 Vaccinia virus (strain Western Reserve) VACWR117 gene Proteins 0.000 description 1
- 101100498120 Vaccinia virus (strain Western Reserve) VACWR118 gene Proteins 0.000 description 1
- 101100054204 Vaccinia virus (strain Western Reserve) VACWR156 gene Proteins 0.000 description 1
- 241000036581 Vaccinia virus Western Reserve Species 0.000 description 1
- 101100049497 Variola virus (isolate Human/India/Ind3/1967) C14L gene Proteins 0.000 description 1
- 101100219276 Variola virus (isolate Human/India/Ind3/1967) C4L gene Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 102220469732 Voltage-dependent L-type calcium channel subunit beta-2_S53A_mutation Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000001678 brown HT Substances 0.000 description 1
- 102220432740 c.127G>T Human genes 0.000 description 1
- 102220432830 c.25T>C Human genes 0.000 description 1
- 102220396600 c.464A>C Human genes 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 241001492478 dsDNA viruses, no RNA stage Species 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009092 lines of therapy Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102200061297 rs121909233 Human genes 0.000 description 1
- 102200081460 rs121913596 Human genes 0.000 description 1
- 102220112903 rs140626538 Human genes 0.000 description 1
- 102200049693 rs141138948 Human genes 0.000 description 1
- 102220100916 rs145959045 Human genes 0.000 description 1
- 102220265843 rs1554890388 Human genes 0.000 description 1
- 102220010468 rs281864950 Human genes 0.000 description 1
- 102220150371 rs531700272 Human genes 0.000 description 1
- 102220046165 rs587782698 Human genes 0.000 description 1
- 102220059022 rs786201869 Human genes 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Oncolytic viruses specifically infect, replicate in, and kill tumor cells while leaving normal cells undamaged. This preference for the transformed cells pegs oncolytic viruses as ideal candidates for the development of new cancer therapies.
- Various oncolytic viruses have been utilized to employ their tumor-specific killing activities by both direct (e.g. cell lysis due to viral replication and immune-mediated cytotoxicity), and indirect mechanisms (e.g. stimulation of the bystander cell killing, induction of cytotoxicity, etc.).
- Oncolytic vaccinia virus is an appealing addition to the current treatment options, demonstrating efficacy and safety in animal models and in early clinical studies. In addition to infecting and killing tumor cells directly, VV may also induce a T-cell response against tumor antigens, increasing the efficiency of the killing.
- viruses this specificity toward cancer cells is naturally occurring (e.g. vesicular stomatitis virus, reovirus, mumps virus)
- viruses can be genetically modified to improve their tumor specificity as well as to reduce their ability to induce antiviral immune response (e.g. adenovirus, measles virus, polio, and vaccinia virus).
- viruses can be engineered to express genes that enhance antitumor immunity by recruitment of natural killer (NK) cells and T cells.
- oncolytic viruses are hindered by the strong immune response induced by the virus.
- Immune factors such as antibodies neutralize the virus by binding to it directly and preventing a successful infection of the cells or by marking it for destruction either by complement or by other immune cells.
- the immune response is faster and stronger, which significantly restricts the ability of the virus to persist long enough to reach the tumor.
- a direct injection of the virus into the tumor overcomes this limitation and delivers all the viral particles directly to the cancer cells.
- this approach may not be suitable for some tumors and does not take into the account cases in which the tumors may have metastasized to other locations.
- a more desirable systemic administration of the virus exposes it to the host immune system capable of recognizing and eliminating potential pathogens.
- Immune factors such as neutralizing antibodies (NAbs) recognize and bind viral glycoproteins with high affinity and prevent virus interaction with host cell receptors, leading to virus neutralization.
- Several oncolytic viruses such as adenovirus, herpes simplex virus, and vesicular stomatitis virus, have been genetically attenuated to placate their ability to induce antiviral defenses and improve tumor specificity.
- Oncolytic vaccinia virus is the most studied member of the Poxviridae and is a large, enveloped, dsDNA virus. Strains highly specific to the tumor cells have been reported. VV’s ability for rapid replication results in efficient lysis of infected cells as well as spread to other tumor cells upon successive rounds of replication, leading to profound localized destruction of the tumor.
- the VV genome encodes ⁇ 250 genes and can accept as much as 20 kb of foreign DNA, making it ideal as a gene delivery vehicle.
- the recombinant VV vectors are being developed to deliver eukaryotic genes, such as tumor-associated antigens, to the tumors and thus facilitate an induction of the host immune system directed to kill the cancer cells.
- VVs cancer treatment delivery vectors
- the NAbs recognize and bind viral glycoproteins embedded in the VV envelope, thus preventing virus interaction with host cell receptors.
- a number of VV glycoproteins involved in host cell receptor recognition have been identified. Among them, proteins H3L, L1R, A27L, D8L, A33R, and B5R have been shown to be targeted by NAbs, with A27L, H3L, D8L and L1R being the main NAb antigens presented on the surface of mature viral particles.
- A27L, H3L, and D8L are the adhesion molecules that bind to host glycosaminoglycans (GAGs) heparan sulfate (HS) (A27L and H3L) and chondroitin sulfate (CS) (D8L) and mediate endocytosis of the virus into the host cell.
- GAGs glycosaminoglycans
- HS heparan sulfate
- CS chondroitin sulfate
- Vaccinia virus is the prototype virus of the orthopoxvirus genus in the family Poxviridae, which replicates in the cytoplasm of cells and encodes more than 200 open reading frames (ORFs) in a 190-kb double-stranded DNA genome.
- Vaccinia virus infection produces multiple forms of infectious particles, namely, intracellular mature virions (IMV), intracellular enveloped virions (IEV), cell-associated enveloped virions (CEV), and extracellular enveloped virions (EEV).
- IMV intracellular mature virions
- IEV intracellular enveloped virions
- CEV cell-associated enveloped virions
- EEV extracellular enveloped virions
- the IMV is the most abundant virion, with a single membrane in cells. IMVs are released only during cell lysis.
- IMVs efficiently infect neighboring cells via interactions between cell receptors and viral glycoproteins imbedded in the IMV membrane.
- a portion of the IMV is subsequently wrapped with two layers of Golgi membrane to form an IEV, which is transported through microtubules to the cell periphery and loses one membrane during virion egress to become a CEV.
- a small percentage ( ⁇ 5%) of the IMVs is moved toward the cell’s periphery where it acquires an outer envelope via fusion with the cell plasma membrane and is subsequently released into the extracellular space as an EEV.
- EEV is composed of the viral DNA core, the intermediate IMV, and an outermost membrane.
- This outer membrane is fragile and can be easily lost, thus EEVs are easily converted to the IMVs exposing the IMV imbedded antigens.
- the IMV is robust and is known to be resistant to environmental and physical changes, whereas the CEV and EEV are very fragile, and the integrity of their outer membranes can be destroyed during purification procedures.
- the 81 viral proteins in IMV are A2.5L, A3L, A4L, A5R, A6L, A7L, A9L, A10L, A12L, A13L, A14L, A14.5L, A15L, A16L, A17L, A18R, A21L, A22R, A24R, A25L, A26L, A27L, A28L, A29L, A30L, A31R, A32L, A42R, A45R, A46R, B1R, C6L, DIR, D2R, D6R, D7R, D8L, D11L, D12L, D13L, E1L, E4L, E6R, E8R, E10R, E11L, F8L, F9L, F10L, F17R, GIL, G3L, G4L, G5R, G5.5R, G7L, G9R, H1L, H2R, H3L, H4L, H5
- IMV proteins A27L, H3L, L1R, and D8L have been identified as major immunogenic proteins.
- IMV proteins A27L, H3L, and D8L are the adhesion molecules that bind to host glycosaminoglycans (GAGs) heparan sulfate (HS) and chondroitin sulfate (CS) (D8L) and mediate endocytosis of the virus into the host cell.
- GAGs glycosaminoglycans
- HS heparan sulfate
- CS chondroitin sulfate
- VV H3L is the membrane protein tethered to the membrane of the mature viral particles post-translationally via its hydrophobic region in the C-terminus.
- H3L is an immunodominant antigen in the anti-VV Ab response and a direct target of NAbs in humans immunized by the smallpox vaccine. Strong immune responses to H3L have also been shown in mice and rabbits. To date, the exact epitopes on H3L that are recognized by the NAbs have not been elucidated.
- D8L is the VV envelope protein expressed early in infection and is involved in viral adhesion to host cells. While A27L and H3L interact with the HS host cell receptors, D8L binds to the CS receptors via its N-terminal domain (between residues 1-234). As one of the main viral antigens, D8L elicits a strong NAb response with the NAbs targeting the CS-binding region on the D8L and blocking viral adhesion to the cells.
- Abs targeting the D8L protein have been described. One of these Abs neutralized VV in the presence of a complement and targeted a conformational epitope on D8 (between residues 41 to 220).
- Residues R44, K48, K98, K108, and R220, a region adjacent to the CS binding site on D8L, are also important for Ab binding.
- N9, E30, T34, T35, N46, F47, K48, G49, G50, Y51, N59, E60, L63, S64, D75, Y76, H95, W96, N97, K99, Y101, S102, S103, Y104, E105, E106, K108, HI 10, D112, Q122, LI 24, D126, K163, T187, P188, and N190 have been identified as D8 antibody binding sites. It is not known whether mutation of these residues will confer sufficient escape from neutralization antibodies. Furthermore, whether mutations of these residues will impair virus packaging and cell entry due to D8L’s role in cell entry remain to be determined.
- L1R is a transmembrane protein found on the surface of the mature VV particles. Its transmembrane domain lies in the C-terminal regions of the protein between residues 186 and 204. L1R is encoded by the L1R ORF, is highly conserved, and plays an essential role in viral entry and maturation. As one of the main targets of anti-VV NAb, L1R is included as a component of the poxvirus protein subunit and DNA vaccines. The NAb binding epitopes on the L1R protein have been characterized.
- A27L is a 14-kDa protein in the envelope of the intracellular mature virus (IMV) that functions in viral host cell recognition and entry. It binds to the HS receptor on the host cell surface via its N-terminal domain (residues 21 to 30) and is attached to the VV envelope by interacting with the envelope protein A17 through its C-terminal domain.
- IMV intracellular mature virus
- a recent study has identified several linear epitopes on the A27L that are recognized by the anti-A27L Abs. The Abs were categorized into four different groups with the Abs in group I binding to the peptide (residues 31 to 40) adjacent to the HS binding site and showing potent virus neutralization in the presence of complement.
- Crystal structures of the full-length A27L in a complex with these Abs identified residues E33, 135, V36, K37, and D39 to be critical for binding. Alanine substitutions of these residues resulted in the decreased ability of the Abs to bind to the peptide.
- a further analysis of the structures showed that residues K27, A30, R32, A34, E40, R107, PI 08, and Y109, although not critical, also contribute to the A27L-Ab binding.
- ways to reduce induction of antiviral defenses and enhance anti -turn or activities include strategies for resisting neutralizing antibodies, overcoming complement- mediated virus neutralization, arming vaccinia viruses with bi-specific polypeptides to boost virus therapy, and/or incorporating immune checkpoint molecules to boost virus therapy.
- the present invention provides mutant vaccinia viruses that are useful as viral vectors and vaccines.
- recombinant vaccinia viruses comprising variant H3L, D8L, A27L and/or L1R viral proteins, including those of SEQ ID NOs:170 and 172.
- recombinant vaccinia viruses comprising a heterologous nucleic acid encoding one of the following polypeptides: a domain of CD55 protein, a bi specific polypeptide that binds to CD3e and FAP (fibroblast activation protein), a bi-specific polypeptide that binds to CD3e and BCMA (B-cell maturation antigen), and a fusion polypeptide comprising human PD-1 extracellular domain.
- the present invention provides mutant vaccinia viruses and uses thereof.
- mutant vaccinia viruses having one or more mutation in the genes encoding proteins involved in binding neutralization antibodies or T cells. These mutations result in mutant vaccinia viruses having the ability to escape vaccinia virus-specific neutralization antibodies or T cells when compared to the wild-type virus.
- the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, the recombinant VV virion comprises a heterologous nucleic acid and one or more of:
- VV vaccinia virus
- VV vaccinia virus
- VV vaccinia virus
- VV vaccinia virus
- VV vaccinia virus
- VV variant vaccinia virus
- D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 6 or SEQ ID NO: 174
- VV variant vaccinia virus
- H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 170;
- VV vaccinia virus
- the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a nucleic acid encoding part or all of a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, and the like, and uses thereof.
- a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, and the like, and uses thereof.
- the complement activation modulators results in recombinant vaccinia viruses having the ability to modulate complement activation and reduce complement- mediated virus neutralization when compared to the wild-type virus.
- the CD55 protein comprises the amino acid sequence of SEQ ID NO:7.
- the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a bi-specific FAP-CD3 scFv that comprises an amino acid sequence having the sequence of SEQ ID NO:8.
- VV vaccinia virus
- FAP-CD3 scFv bi-specific FAP-CD3 scFv that comprises an amino acid sequence having the sequence of SEQ ID NO:8.
- the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a bi-specific BCMA-CD3 scFv that comprises an amino acid sequence having the sequence of SEQ ID NO:9.
- VV vaccinia virus
- the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a PD-l-ED-hlgGl-Fc fusion peptide that comprises an amino acid sequence having the sequence of SEQ ID NO: 10.
- VV vaccinia virus
- the present invention provides a method of delivering a gene product to an individual in need thereof, the method comprising administering to the individual an effective amount of an infectious recombinant vaccinia virus (VV) virion or recombinant oncolytic viruses disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the recombinant virion.
- VV infectious recombinant vaccinia virus
- a pharmaceutical composition comprising the recombinant vaccinia virus (VV) virion or recombinant oncolytic viruses disclosed herein, and methods of using such composition to treat cancer.
- a library comprising one or more variant vaccinia virus (VV) virions, each of said variant VV virions comprises one or more variant VV protein, the variant VV protein comprises an amino acid sequence having at least one amino acid substitution relative to the amino acid sequence of a corresponding wild type VV protein.
- VV vaccinia virus
- the present invention provides a method of delivering a gene product to an individual in need thereof, the method comprises administering to the individual an effective amount of infectious variant vaccinia virus (VV) virions derived from the above library, wherein the gene product is encoded by a nucleic acid carried by such variant VV virions.
- VV infectious variant vaccinia virus
- a pharmaceutical composition comprising variant vaccinia virus (VV) virions derived from the above library, and methods of using such composition to treat cancer.
- VV vaccinia virus
- a recombinant vaccinia virus H3L protein that has at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to one of SEQ ID NOs:l, 5 or 170.
- a recombinant vaccinia virus D8L protein that has at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NOs:6, 172 or 174.
- Figures 1A-C show neutralizing antibody (Nab) epitope determination of H3L - peptide arrays sequence analysis.
- Antibody 35219 was used for binding to the peptide array of the H3L sequence (Ab35219 is a rabbit polyclonal to VV; Immunogen: Native virus, Lister strain).
- Figure 1A shows diagram of the SPOT-synthesis peptide array.
- Figure IB shows autoradiograph of the H3L peptide array probed by ab35219.
- the peptide array consists of spots of 12-residue peptides in the H3L sequence, starting from the N terminus (spot 1) and ending with the C-terminal peptide (spot 69), with the N-terminal residue of the peptide in each spot shifted by 4 residues from the previous spot along the H3L sequence.
- Figure 1C are graphs showing signal intensity (y axis) of each spot (black bars) (x axis).
- Figures 2A-B show NAb epitope mapping of H3L by linear peptide ELISA.
- Figure 2A shows ELISA results for H3L peptides 1 - 4.
- Figure 2B shows ELISA results for H3L peptides 5 - 9.
- Arrows indicate some examples of alanine-substituted residues that have an effect on antibody (Ab) binding.
- a lower optical density (OD) indicates that the alanine-substituted peptide preincubated with the Ab binds sufficiently to prevent the Ab binding to plate-bound native peptide.
- a higher OD indicates the decreased ability of the mutant peptide to interact with the Ab, signifying that the mutated residue is important for H3L binding to Ab.
- Figures 3A-D show construction of modified H3L, D8L, L1R, and A27L plasmids.
- Figure 3A shows a construct containing the H3L promoter, H3L ORF (with mutated nucleotides), and approximately ⁇ 250-bp flanking regions containing the H4L (left flank) and the H2R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figure 3B shows a construct containing the D8L promoter, D8L ORF (with mutated nucleotides), and approximately ⁇ 250-bp flanking regions containing the D9R (left flank) and the D7R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figure 3C shows a construct containing the L1R promoter, L1R ORF (with mutated nucleotides), and approximately ⁇ 250-bp flanking regions containing the G9R (left flank) and the L2R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figure 3D shows a construct containing the A27L promoter, A27L ORF (with mutated nucleotides), and approximately ⁇ 250-bp flanking regions containing the A28-A29L (left flank) and the A26L (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- GFP green fluorescent protein
- Figure 4 shows identification of the correct H3L, D8L, L1R, and A27L recombinant clones. Single plaques were purified and correct gene insertions were confirmed by PCR.
- Figure 5 shows plaque reduction neutralization tests (PRNTs) using polyclonal anti- VV Abs.
- a panel of five anti-VV polyclonal antibodies consisting of ab35219 (Abeam) - rabbit polyclonal to VV (Immunogen: Native virus, Lister strain), ab21039 (Abeam) - rabbit polyclonal to VV (Immunogen: Lister Strain (mixture of virions and infected cell polypeptides)), ab26853 (Abeam) - rabbit polyclonal to VV (Immunogen: Synthetic peptide containing amino acids on the predicted N terminus of A27L in VV), 9503-2057 (Bio-Rad) - rabbit polyclonal against VV Ab (Immunogen: Vaccinia virus, New York City Board of Health (NYCBOH) strain), and PA1-7258 (Invitrogen) - rabbit polyclonal against VV (Immunogen: NYCBOH strain and Lister strain)
- Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the escape variant or the wt VV virus (control) in the presence of sterile baby rabbit complement. The mixture was then added to the CV-1 cells and 48 hrs later cells were stained and plaques counted. Whereas 83.3-95.5% of the control VV virus was neutralized across the panel, the escape variant (FAP-VVNEV) showed a significantly lower neutralization by the Abs (7.88- 66.1%). Error bars are based on two or three data points per sample.
- FIG. 6 shows VV EM (vaccinia virus escape mutant) in vitro plaque reduction neutralization test with anti-VV polyclonal Abs.
- VV EM was isolated from the mutant VV library pool in the presence of anti-VV polyclonal antibodies.
- Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the VV EM or the wild type VV virus (control) in the presence of sterile baby rabbit complement.
- VV EM showed a significantly lower (30.7-66.9%) neutralization by the Abs. Error bars are based on two or three data points per sample. VV EM was further sequenced to identify the mutation within H3, LI, A27, or D8 that might be responsible for the Nab escape.
- Figure 7 shows results of a recombinant virus replication assay.
- Prior to infection virus was preincubated with Ab 9503-2057 (40 pg/mL) for 1 hour at 37°C. Samples were collected at 24, 48, and 72 hours and titers were determined for each time point.
- the recombinant virus was significantly more efficient in replicating in the presence of Ab, compared to the control Ab, which was almost entirely inactivated.
- Figure 8 shows anti-tumor efficiency of the recombinant virus.
- Cells were incubated for 48 hours and cell viability was measured by MTS assay (colorimetric assessment of cell metabolic activity). Briefly, cells collected at 48 hours were washed once with PBST and resuspended at 1 c 105 cells/mL in complete DMEM. One hundred pL of each cell suspension was added to a 96-well (in triplicates).
- Figure 9 shows a recombinant W NEV in vitro plaque reduction neutralization test with anti-VV polyclonal Abs.
- Anti-VV polyclonal antibodies 9503-2057 and PA1-7258 were used to test VV EM for neutralization escape in vitro.
- Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the W NEV (right panel) or the wild type vaccinia virus (control, left panel) in the presence of sterile baby rabbit complement.
- Figure 10 shows results of a recombinant virus replication assay.
- Figure 11 shows a CD55-A27-VV construct containing the A27 promoter, CD55-ED, A27, loxP -flanked tag, and flanking regions containing the A27L (left flank) and the A27R (right flank). ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figure 12 shows CD55-NEV escapes complement-mediated neutralization effectively in vitro.
- Figure 13 shows CD55-NEV escapes neutralization antibody and complement- mediated neutralization effectively in vitro.
- Figure 14 shows aFAP-TEA-NEV construct containing the F17R promoter, FAP-CD3 scFv, loxP -flanked tag, and flanking regions containing the TKL (left flank) and the TKR (right flank).
- ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figure 15 shows a FAP-TEA-NEV enhanced tumor lysis and human T cell proliferation in vitro (see circle, microscopy observation).
- Figure 16 shows a FAP-TEA-NEV induced tumor cell apoptosis effectively (flow cytometry analysis).
- Figure 17 shows MFI of apoptosis marker PI staining of gated U87 tumor cells.
- Figure 18 shows a bispecific FAP-CD3 scFv expressed by FAP-TEA-NEV enhanced bystander tumor lysis in vitro (see circles, microscopy observation).
- Figure 19 shows a BCMA-TEA-NEV construct containing the F 17 promoter, BCMA- CD3 scFv, loxP -flanked GFP-tag, and flanking regions containing the TKL (left flank) and the TKR (right flank). ORF sequences was synthesized by GENEWIZ and cloned into the pUC57- Amp plasmid.
- Figures 20A-B show flow cytometric analysis of co-culture of BCMA-positive RMPI- 8226 MM and Jurkat T cells.
- Figures 21A-B show ELISA measurement of IFNy and IL2 expression by Jurkat T cells following 24 hours co-culture with BCMA-positive RMPI-8226 MM.
- Figure 22 shows a PD-l-ED-hlgGl-Fc-VV construct containing the pE/L promoter, PD-l-ED-hlgGl-Fc, loxP -flanked GFP-tag, and flanking regions containing the TKL (left flank) and the TKR (right flank).
- ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- Figures 23A-B show flow cytometric analysis of co-culture of PD-L1 -positive Raji cells and CD 16-positive Jurkat T cells.
- Figure 24A-B show ELISA measurement of IFNy and IL2 expression by CD 16- positive Jurkat T cells following 24 hours co-culture with PD-L1 -positive Raji cells.
- Figure 25 shows the luciferase activity measurement of CD 16-positive Jurkat T cells following 24 hours co-culture with PD-L1 -positive Raji cells.
- the present invention discloses the making and uses of variant vaccinia virus (VV) virions that have reduced ability to induce antiviral defenses and have enhanced anti-tumor activities.
- VV vaccinia virus
- the present invention discloses the making and uses of recombinant oncolytic viruses that have reduced ability to induce antiviral defenses and have enhanced anti-tumor activities.
- the variant vaccinia virus (W) virions of the present invention have increased resistance to anti-VV neutralizing antibodies.
- the variant vaccinia virus virions of the present invention comprise one or more variant VV proteins (such as H3L protein, D8L protein, A27L protein, and L1R protein) that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies.
- the present specification discloses experiments studying variant VV protein H3L.
- the same experimental setup can be used to study other vaccinia virus viral proteins such as D8L protein, A27L protein, L1R protein etc.
- peptide arrays encompassing the full-length viral protein was synthesized and screened for peptides that bound the anti-VV neutralizing antibodies. Peptides thus identified were further examined to elucidate the neutralizing antibody epitopes.
- variants of the peptides identified by the peptide array were synthesized with alanine substitutions, and the neutralizing antibody epitopes were mapped using a series of ELISA binding assays. Once the neutralizing antibody epitopes were identified, mutations that destroy these epitopes can be introduced into the VV genome by genetic engineering.
- the present invention discloses a number of neutralizing antibody epitopes on each of the vaccinia virus H3L protein, D8L protein, A27L protein, and L1R protein. Mutating or substituting amino acid(s) at these neutralizing antibody epitopes would confer viral escape from the neutralizing antibodies. Similarly, deleting amino acid(s) at these neutralizing antibody epitopes is also expected to confer viral escape from the neutralizing antibodies. Hence, it is expected that deletion of one or more amino acids within the H3L, D28L, A27L, L1R viral protein, or deletion of the whole H3L, D28L, A27L, or L1R viral protein could also confer escape from neutralizing antibody binding. H3L deletion mutant variants have been reported, indicating the feasibility of generating one or more amino acid deletion or whole protein deletion virus mutants, even though the H3L deletion impaired the virus mutant’s infectivity and replication capability.
- the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, comprising a heterologous nucleic acid and one or more of: a) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:l; b) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:2; c) a variant vaccinia virus (VV) A27L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:3; d) a variant vaccinia virus (VV) L1R protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:
- the above variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34,
- SEQ ID NO:l 250, 253, 254, 255, and 256 of SEQ ID NO:l. Any suitable amino acids can be used in the substitutions.
- variant peptides can be synthesized with substitutions.
- the above variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 44, 48, 98, 108, 117, and 220 of SEQ ID NO:2. Any suitable amino acids can be used in the substitutions.
- variant peptides can be synthesized with substitutions.
- the above variant VV A27L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 27, 30, 32, 33, 34, 35, 36, 37, 39, 40, 107, 108, and 109 of SEQ ID NO:3. Any suitable amino acids can be used in the substitutions.
- variant peptides can be synthesized with substitutions.
- the above variant VV L1R protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 25, 27, 31, 32, 33, 35, 58, 60, 62, 125, and 127 of SEQ ID NO:4. Any suitable amino acids can be used in the substitutions.
- variant peptides can be synthesized with substitutions.
- the above variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34,
- the above variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 43, 44, 48, 53, 54, 55, 98, 108, 109, 144, 168, 177, 196, 199, 203, 207, 212, 218, 220, 222, and 227 of SEQ ID NO: 172. Any suitable amino acids can be used in the substitutions.
- Complement is a key component of the innate immune system, targeting the virus for neutralization and clearance from the circulatory system. Complement could enhance neutralization antibody’s neutralizing efficacy, and antibody -mediated protective immunity induced by smallpox vaccination was largely decreased in vitro in the absence of complement, indicating the critical role of complement in the neutralization of vaccinia virus. Complement activation results in cleavage and activation of C3 and deposition of opsonic C3 fragments on surfaces. Subsequent cleavage of C5 leads to assembly of the membrane attack complex (C5b, 6, 7, 8, 9), which disrupts lipid bilayers.
- Complement activation can be negatively regulated by several membrane regulator of complement activation (RCA).
- RCAs downregulate complement activation at different steps.
- CD35 complement receptor 1
- CD55 decay-accelerating factor
- CD35 and CD46 membrane cofactor protein
- CD59 prevents the formation of the membrane attack complex.
- EEV extracellular enveloped vaccinia virus
- the present invention provides recombinant vaccinia virus (VV) virions comprising a heterologous nucleic acid encoding a part or all of a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPINGl), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, or other identified complement activation modulators, and uses thereof.
- a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPINGl), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, or other identified complement activation modulators, and uses thereof.
- the complement activation modulators results in recombinant vaccinia viruses having the ability to modulate complement activation and reduce complement-mediated virus neutralization as compared to the wild-type virus.
- the heterologous nucleic acid carried by the above recombinant vaccinia virus (VV) virion encodes a complement activation modulators or a fragment thereof.
- the complement activation modulator can be human CD55, CD59, CD46, CD35, factor H, C4- binding protein, Cl inhibitor (Cl-INH, SERPINGl), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, or other identified complement activation modulators.
- the heterologous nucleic acid encodes a CD55 protein that comprises an amino acid sequence having the sequence of SEQ ID NO:7.
- complement activation modulators e.g. CD59, CD46, CD35, factor H, C4-binding protein etc
- the above invention of overcoming complement-mediated virus neutralization is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding a polypeptide that confers to the viruses resistance to antiviral defenses or enhanced anti-tumor activities.
- oncolytic viruses include, but are not limited to, adenovirus, adeno-associated virus, alphavirus, coxsackievirus, echovirus, flavivirus, maraba virus, measles virus, myxoma virus, herpes simplex virus (hsv), newcastle disease virus, parvovirus, picornavirus, poliovirus, poxvirus, reovirus, rhabdovirus, semliki forest virus, seneca valley virus, vaccinia virus, vesicular stomatitis virus, or hybrid viral vectors derived from the above oncolytic viruses.
- the heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof.
- regulator of complement activation examples include, but are not limited to, CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI), S-protein (vitronectin), clusterin (SP-40), or Ml protein.
- Cl inhibitor Cl-INH, SERPING1
- CFHR-1 CFH-related protein
- thrombomodulin Factor 1
- CFI Factor 1
- S-protein vitronectin
- SP-40 clusterin
- Ml protein Ml protein.
- the heterologous nucleic acid encodes a CD55 protein that comprises an amino acid sequence having the sequence of SEQ ID NO:7.
- Oncolytic virus can be armed to express bi-specific antibodies that bind to a first antigen on immune cells and a second antigen on tumor cells.
- first antigen on immune cells include, but are not limited to, CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D, and the like.
- Examples of the second antigen on tumor cells include, but are not limited to, EphA2, HER2, GD2, Glypican-3, 5T4, 8H9, avb6 integrin, B7-H3, B7-H6, BCMA, CADC, CA9, CD 19, CD20, CD22, kappa light chain, CD30, CD33, CD38, CD44, CD44v6, CD44v7 /8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, EGFRvl 11, EGP2, EGP40, EPCAM, ERBB3, ERBB4, ErbB3/4, FAP, FAR, FBP, fetal AchR, Folate Receptor a, GD2, GD3, HLA-AI MAGE Al, HLA-A2, ILl lRa, IL13Ra2, KDR, Lambda, Lewis-Y, MCSP, Mesothelin, Mucl, Mucl6, NCAM, NKG2D ligands
- Maturation Antigen BCMA1 To Treat Multiple Myeloma
- MUS monoclonal gammopathy of undetermined significance
- MM is a malignancy of clonal plasma cells derived from the B- lymphocyte lineage that is part of a spectrum of diseases ranging from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell leukemia. It is the second most common hematological cancer in the United States with an estimated 32,110 newly diagnosed cases and 12,960 deaths in 2019. MM currently accounts for 10% of hematological malignancies and 2.1% of all cancer-related deaths.
- VV Oncolytic vaccinia virus
- VV can express T-cell engager targeting or co-targeting MM antigens, such as BCMA, CD 19, CD26, CD38, CD44v6, CD56, CD138, CS1, EGFR, integrin beta7, KIRs, LIGHT/TNF SF 14, NKG2D, PD-1/PD-L1, SLAMF7, TACI, and TGIT.
- B-cell maturation antigen BCMA
- TNFRSF17 tumor necrosis factor receptor superfamily 17
- PC plasma cells
- BCMA-targeted chimeric antigen receptor (CAR) T-cells showed significant clinical activities in patients with relapsed and refractory multiple myeloma (RRMM) who have undergone at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent.
- Anti-BCMA Ab-drug conjugate (ADC) also has achieved significant clinical responses in patients who failed at least three prior lines of therapy.
- Both BCMA-targeted CAR-T and ADC were granted breakthrough status for patients with RRMM by FDA in Nov 2017. As promising as these two therapies are there are several complicating factors for targeting BCMA.
- anti-BCMA treatment will potentially reduce the number of long-lived PCs and, since long-lived PCs play a critical role in maintaining humoral immunity, the impact of anti-BCMA therapy on immune function needs to be carefully and serially evaluated.
- the present invention provides recombinant vaccinia virus (VV), BCMA-TEA-NEV, that overcomes the limitations discussed above because the BCMA-CD3 BiTE expression will be limited within the MM surrounding area while escaping the BCMA+ PCs and sBCMA.
- TEA-NEV encodes bi-specific scFvs that directs T cells to recognize and kill tumor cells that are not infected with VV (by-stander killing), resulting in enhanced tumor lysis.
- the CD3-scFv promotes T-cell infiltration into tumors and their activation, and the cytokines they release upon activation create a pro-inflammatory micro-environment that inhibites tumor growth.
- the TEA-NEV induces local production of T-cell engager that allows for higher concentrations of T cells at the target site while reducing systemic side effects.
- arming oncolytic VV with bi-specific scFvs is important to engage T cells for cancer therapy and produce the desired increase in anti-tumor activity of current VV by inducing by-stander killing.
- the heterologous nucleic acid carried by the above recombinant vaccinia virus (VV) virion encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen, B-cell maturation antigen (BCMA), on multiple myeloma (MM).
- the bi-specific polypeptide is abi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human BCMA (B-cell maturation antigen).
- such bi-specific scFvs comprises an amino acid sequence of SEQ ID NO:9.
- VV can express T-cell engager targeting or co-targeting other MM antigens, such as CD 19, CD38, SLAMF7, CD26, LIGHT/TNFSF14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
- the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP (fibroblast activation protein) that is overexpressed on most epithelial cancers.
- the bi-specific FAP-CD3 scFv comprises the amino acid sequence of SEQ ID NO:8.
- the above invention of incorporating bi-specific antibodies to boost virus therapy is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. Examples of oncolytic viruses have been discussed above.
- the bi-specific polypeptide encoded by the heterologous nucleic acid is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human BCMA (B-cell maturation antigen).
- such BCMA-CD3 scFv comprises an amino acid sequence of SEQ ID NO:9.
- the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP (fibroblast activation protein) that is overexpressed on most epithelial cancers.
- the bi-specific FAP-CD3 scFv comprises the amino acid sequence of SEQ ID NO:8.
- Immune checkpoint molecules are proteins expressed on certain immune cells that need to be activated or inhibited to start an immune response, for example, to attack abnormal cells such as tumor cells in the body.
- the “immune escape” may include several activities by the tumor cells, such as down-regulation of co-stimulatory molecule expression, such as stimulatory immune checkpoint molecules, and up-regulation of inhibitory molecule expression, such as inhibitory immune checkpoint molecules.
- Blockade of these inhibitory immune checkpoint molecules have shown very promising results in preclinical and clinical tests in cancer treatment. However, there are some unwanted side effects in some cases. For example, blocking these inhibitory immune checkpoint molecules (receptors or ligands) may lead to a disruption in immune homeostasis and self-tolerance, resulting in autoimmune/auto-inflammatory side effects.
- Immune checkpoint molecules are well-known in the art.
- the PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are commonly expressed on the surface of dendritic cells or tumor cells.
- PD-1 and PD-L1/PD-L2 belong to the family of inhibitory immune checkpoint proteins that can halt or limit the development of T cell response.
- PD-L1 expressed on the tumor cells could bind to PD-1 receptors on the activated T cells, which leads to inhibition of cytotoxic T cells.
- anti-tumor immune responses would be enhanced by blocking the interaction between PD-1 and its ligands.
- the present invention provides recombinant vaccinia virus (VV) virions that would block the inhibitory PD-1 pathway.
- the present invention provides recombinant vaccinia virus (VV) virions comprising a heterologous nucleic acid encoding an extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl).
- the PD-1 fusion protein (PD-l-ED-hlgGl-Fc) comprises the amino acid sequence of SEQ ID NO: 10.
- other immune checkpoint molecules can be readily incorporated into the recombinant vaccinia virus presented herein.
- the recombinant vaccinia viruses disclosed herein may comprise immune checkpoint molecules including, but not limited to, PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
- immune checkpoint molecules including, but not limited to, PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
- the above invention of incorporating immune checkpoint molecules to boost virus therapy is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding an immune checkpoint molecule. Examples of oncolytic viruses have been discussed above. In one embodiment, the present invention provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding an extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl).
- Fc constant domain of immunoglobin-Gl
- the PD-1 fusion protein (PD-l-ED-hlgGl-Fc) comprises the amino acid sequence of SEQ ID NO: 10.
- the recombinant oncolytic viruses disclosed herein may comprise immune checkpoint molecules including, but not limited to, PD-1, PD- LI, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
- the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, the virion comprises a heterologous nucleic acid and one or more of: a) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 1; b) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 2; c) a variant vaccinia virus (VV) A27L protein having at least about 60% amino acid sequence identity to SEQ ID NO:3; d) a variant vaccinia virus (VV) L1R protein having at least about 60% amino acid sequence identity to SEQ ID NO: 4; e) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 5; f) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ
- the variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 198, 227, 250, 253, 254, 255, and 256 of SEQ ID NO: 1.
- the variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 44, 48, 98, 108, 117, and 220 of SEQ ID NO:2.
- the variant VV A27L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 27, 30, 32, 33, 34, 35, 36, 37, 39, 40, 107, 108, and 109 of SEQ ID NO:3.
- the variant VV L1R protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 25, 27, 31, 32, 33, 35, 58, 60, 62, 125, and 127 of SEQ ID NO:4.
- the variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 132, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 195, 198, 199, 227, 250, 251, 252, 253, 254, 255, 256, 258, 262, 264, 266, 268, 272, 273, 275, and 277 of SEQ ID NO: 170.
- the variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 43, 44, 48, 53, 54, 55, 98, 108, 109, 144, 168, 177, 196, 199, 203, 207, 212, 218, 220, 222, and 227 of SEQ ID NO: 172.
- the heterologous nucleic acid carried by the recombinant VV encodes a regulator of complement activation or a fragment thereof.
- regulator of complement activation include, but are not limited to, CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), or Ml protein.
- the heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
- the heterologous nucleic acid carried by the recombinant VV encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells.
- the first antigen on immune cells can be CD3, CD4, CD5, CD8, CD 16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, or NKG2D.
- the second antigen on tumor cells can be fibroblast activation protein (FAP), or tumor antigens on multiple myeloma.
- FAP fibroblast activation protein
- the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP.
- this bi-specific polypeptide has the amino acid sequence of SEQ ID NO: 8.
- the bi-specific polypeptide can target tumor antigens on multiple myeloma, e.g. B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNF SF 14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, or CD44v6.
- BCMA B-cell maturation antigen
- the bi-specific polypeptide is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human BCMA.
- this bi-specific polypeptide has the amino acid sequence of SEQ ID NO:9.
- the heterologous nucleic acid carried by the recombinant VV encodes a fusion polypeptide comprising an immune checkpoint molecule.
- immune checkpoint molecule include, but are not limited to, PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD160, 2B4, and CD73.
- the heterologous nucleic acid carried by the recombinant VV encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, e.g., this fusion polypeptide has the amino acid sequence of SEQ ID NO: 10.
- the recombinant vaccinia virus (VV) virion disclosed herein exhibits resistance to neutralizing antibodies compared to the resistance exhibited by wild type VV.
- the recombinant vaccinia virus (VV) virion disclosed herein exhibits increased transduction of mammalian cells in the presence of anti-VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
- a method of delivering a gene product to a subject (human or animal) in need thereof includes administering to the subject an effective amount of the recombinant vaccinia virus (VV) virion disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the recombinant VV virion.
- VV vaccinia virus
- a pharmaceutical composition comprising the recombinant vaccinia virus (VV) virions disclosed herein and a pharmaceutically acceptable carrier.
- a method of using such pharmaceutical compositions to treat cancer in a subject can be administered to the subject intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, enteral administration (e.g. through the gastrointestinal tract), or other systemic administration approach generally known in the art.
- the subject is a human.
- the present invention may also be used in administration to and treatment of animal subjects.
- a library comprising one or more variant vaccinia virus (VV) virions, each of the variant W virions comprises one or more variant VV protein.
- the variant VV protein comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein.
- the variant VV protein can be variant H3L protein, variant D8L protein, variant L1R protein, and/or variant A27L protein.
- the variant VV protein comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence set forth in one of SEQ ID NOs:5, 6 or 174.
- variant vaccinia virus (VV) virions derived from the above library, the virions comprises a heterologous nucleic acid and one or more variant VV proteins, wherein at least one of the variant VV proteins comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein.
- the heterologous nucleic acid carried by such variant VV virions encodes a regulator of complement activation or a fragment thereof. Examples of regulator of complement activation such as CD55 and others have been described above.
- the heterologous nucleic acid encodes a CD55 protein that comprises the amino acid sequence of SEQ ID NO:7.
- the heterologous nucleic acid encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. Examples of such first antigen and second antigen have been discussed above.
- the bi-specific polypeptide is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human FAP, e.g. this bi-specific scFvs comprises the amino acid sequence of SEQ ID NO:8.
- the bi-specific polypeptide is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human BCMA, e.g.
- this bi-specific scFvs comprises the amino acid sequence of SEQ ID NO: 9.
- the heterologous nucleic acid encodes a fusion polypeptide comprising an immune checkpoint molecule as discussed above.
- the fusion polypeptide comprises human PD-1 extracellular domain and a human IgGl Fc domain, the fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
- the variant VV virions derived from the above library exhibit resistance to neutralizing antibodies compared to the resistance exhibited by wild type VV.
- these variant VV virions exhibit increased transduction of mammalian cells in the presence of anti-VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
- VV vaccinia virus
- a pharmaceutical composition comprising variant vaccinia virus (VV) virions derived from the above library and a pharmaceutically acceptable carrier.
- a method of using such pharmaceutical composition to treat cancer in a subject can be administered to the subject intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, enteral administration (e.g. through the gastrointestinal tract), or other systemic administration approach generally known in the art.
- the subject is a human, but the technology may also be used in administration to and treatment of animal subjects.
- a recombinant vaccinia virus (VV) H3L protein that has at least about 60% amino acid sequence identity to one of SEQ ID NOs: 1, 5 or 170.
- a recombinant vaccinia virus D8L protein that has at least about 60% amino acid sequence identity to one of SEQ ID NOs:2, 6, 172 or 174.
- the present invention also provides a recombinant oncolytic virus comprising a heterologous nucleic acid encoding a polypeptide that confers to said virus resistance to antiviral defenses or enhanced anti-tumor activities.
- oncolytic viruses include, but are not limited to, adenovirus, adeno-associated virus, alphavirus, coxsackievirus, echovirus, flavivirus, maraba virus, measles virus, myxoma virus, herpes simplex virus (HSV), newcastle disease virus, parvovirus, picornavirus, poliovirus, poxvirus, reovirus, rhabdovirus, Semliki Forest virus, Seneca Valley virus, vaccinia virus, vesicular stomatitis virus, and hybrid viral vectors thereof.
- the heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof.
- regulators of complement activation include, but are not limited to,CD55, CD59, CD46, CD35, factor H, C4 -binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), and Ml protein.
- the heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
- the recombinant oncolytic virus comprises a heterologous nucleic acid encoding a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells.
- first antigens on immune cells include, but are not limited to, CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D.
- Second antigens on immune cells can be fibroblast activation protein (FAP), or tumor antigens on multiple myeloma.
- FAP fibroblast activation protein
- tumor antigens on multiple myeloma include, but are not limited to, B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNFSF14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
- the bi-specific polypeptide is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human FAP
- the bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO:8.
- the bi-specific polypeptide is a bi-specific scFvs
- the first antigen is human CD3e
- the second antigen is human BCMA
- the bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO: 9.
- the recombinant oncolytic virus comprises a heterologous nucleic acid encoding a fusion polypeptide comprising an immune checkpoint molecule.
- immune checkpoint molecules include, but are not limited to, PD-1, PD-L1, PD- L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7- H4, CD 160, 2B4, and CD73.
- the heterologous nucleic acid encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, and the fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
- the recombinant oncolytic virus disclosed herein exhibits resistance to neutralizing antibodies compared to that exhibited by wild type virus. In another embodiment, the recombinant oncolytic virus exhibits increased transduction of mammalian cells in the presence of neutralizing antibodies compared to transduction of mammalian cells by wild type virus.
- a method of delivering a gene product to an individual in need thereof comprising administering to the individual an effective amount of the recombinant oncolytic virus disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the oncolytic virus.
- the present invention provides a pharmaceutical composition comprising the recombinant oncolytic virus disclosed herein and a pharmaceutically acceptable carrier.
- a pharmaceutical composition comprising the recombinant oncolytic virus disclosed herein and a pharmaceutically acceptable carrier.
- a method of using such pharmaceutical composition to treat cancer in a subject e.g. a human or an animal.
- the pharmaceutical composition can be administered to the subject systemically, intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, or enteral administration.
- CV-1 cells ATCC, cat. # CCL-70).
- vSC20 Vaccinia virus stock GeneJuice Transfection Reagent (Millipore, cat. # 2703870).
- DMEM media GE Helathcare, cat. # SH30081.01), FBS (GE Healthcare, cat. # SH30070.03), DPBS (Sigma, cat. # 8537). Dry ice/ethanol bath, 6-well tissue culture plates, 12 c 75-mm polystyrene tubes, disposable scraper or plunger from a 1 ml syringe, sterile 2-ml sterile microcentrifuge tubes.
- CV-1 cells (2 c 10 5 /well) were seeded in wells of a 6-well tissue culture plate in complete DMEM medium and incubate to 50-80% confluency (37 °C, 5% CO2 overnight). An aliquot of parental virus was thawed and sonicated (30 sec) in ice-water several times to remove the clumps (cool on ice between each sonication). Virus was diluted in complete DMEM to 0.5 x 10 5 pfu/ml. Medium was remove from confluent monolayer of cells and cells were infected with 0.5 ml diluted vaccinia virus (0.05 pfu/cell) and incubated 2 hrs at 37°C.
- Transfection mixture was removed after 4-8 hrs incubation and replaced with complete DMEM medium followed by incubation for 24-72 hrs at 37°C (5% C02). After 24-72 hours, the cells were dislodged from the wells and transferred to a 2-ml sterile microcentrifuge tube. The cell suspension was then lysed by performing three freeze-thaw cycles, each time by freezing in a dry ice/ethanol bath, thawing in a 37°C water bath, and vortexing. The cell lysate was stored at -80°C until needed
- CV1 cells (5 c 10 5 /well) were seeded in a 6-well tissue culture plate in complete DMEM medium (2mL/well) and incubate to >90% confluency (37 °C, 5% CO2, 24 hrs).
- One hundred, 10, 1, or 0.1 m ⁇ of lysate were added to duplicate wells containing 1 ml complete DMEM medium and incubate 2 hrs at 37°C.
- the virus inoculum was then removed from the infected cells.
- 2 ml of complete DMEM medium containing 2.5% methylcellulose was added to each well with and incubated 2 days. Two days later, well-separated plaques were picked up by scraping and suction with a pipet tip.
- Fluorescent microscope was used to select GFP+ plaques that was transferred to a tube containing 0.5 ml complete DMEM medium. Each virus- containing tube was vortexed followed by three freeze-thaw cycles, each time by freezing in a dry ice/ethanol bath, thawing in a 37°C water bath, and vortexing.
- CV-1 cells were seeded and grown to 100% confluence in 24 well plate.
- the concentrated virus stock was diluted in 10-fold series dilutions with DMEM infection medium and added to each well. After 36-72 hour incubation, the wells that contain single plaque was marked and kept in the incubator until the whole well got infected, which takes about 4-5 days after initial infection. The infected cells were harvested and the recombination was confirmed by PCR assay. PCR conditions are listed below for each reaction.
- peptide arrays encompassing full-length H3L were synthesized and screened for peptides that bound the anti-VV NAb.
- the array started at the N terminus of H3L and spanned the entire length of the protein sequence, with each successive spot containing 12 amino acids along the sequence shifted by 4 amino acids toward the C terminus, i.e., each spot in the array had an 8-residue overlap with the previous spot.
- Cellulose membrane containing synthesized H3L peptide array was then screened to identify peptides that bound to anti-VV polyclonal NAb (Abeam, ab35219).
- the membrane was washed three times for 5 min in Millipore ThO and blocked overnight at 4°C with 5% (wt/vol) milk-PBS (MPBS).
- MPBS 5% (wt/vol) milk-PBS
- Four pg/mL NAb was incubated with the membrane in MPBS for 3 h at room temperature with gentle agitation. After incubation, membrane was washed six times for 5 min with 20 mL PBS supplemented with 1% Tween 20 (PBST).
- PBST 1% Tween 20
- the peptide-bound NAb was detected by incubating the membrane with 2 pg/ml of rabbit horseradish peroxidase (HRP)-conjugated secondary Ab (Abeam, ab6721) in MPBS for 4 h at 4°C with gentle agitation.
- HRP horseradish peroxidase
- the membrane was then washed three times for 5 min with PBST, incubated in 5 ml of the enhanced chemiluminescence (ECL) developing solution (Thermo Fisher, #32109). Peptides that are positive for binding appear as spots on the membranes (Fig. IB). The signal was visualized, and the intensity of each spot was measured by a CCD camera (GE Healthcare, AmershamTM Imager 600). No over saturation of the spots was detected and after integrating, the intensities of the spots were plotted (Fig. 1C). A signal of ⁇ 110000 was considered background (determined by analysis of the membrane) and the spots showing a signal higher than 1100000 were considered to represent positive binding. Twenty six spots showed binding to ab35219 with higher than the cutoff intensity.
- ECL enhanced chemiluminescence
- PVIDRLP (aa 11-18) (SEQ ID NO:89), NDQKFDDVKDN (aa 30-40) (SEQ ID NO:90), PERKNVVVV (aa 44-52) (SEQ ID NO:91), NVIEDITFLR (aa 128-137) (SEQ ID NO:92), QMREI (aa 152-156) (SEQ ID NO:93), KVKTELVM (aa 161-168) (SEQ IDNO:94), NIVDEIIK (aa 197-204) (SEQ ID NO: 95), KINRQI (aa 224-229) (SEQ ID NO: 96), FENMKPNF (aa 249-265) (SEQ ID NO:97).
- H3L is a glycosyltransferase. Some viruses encode their own glycosyltransferases to aid in host immune response evasion. H3L binds the UDP-Glc via the D/ExD motif in its central domain and mutating this motif (aa 125 and 127, specifically) inhibited the binding.
- the peptide array showed a likely Ab binding site near the D/ExD motif (peptide NVIEDITFLR, aa 128-137 (SEQ ID NO:92)). Binding of the Ab in this region would interfere with the glycosyltransferase activity of the H3L, another possible mechanism of virus neutralization by the Ab.
- Control peptide for set 3 peptides (EKRNVVVV (SEQ ID NO: 169)) showed a signal higher than the rest of the peptides in the set with only two other peptides in this set showing a signal above 0.07.
- the scan identified a total of 29 residues positive for Ab binding: 114, D15, R16, K33, F34, D35, K38, N40, E45, V52, E131, T134, F135, L136, R137, R154, E155, 1156, K161, L166, VI 67, M168, 1198, R227, E250, K253, P254, N255, and F256 (Fig. 2).
- the peptide arrays involve linear peptides and therefore may not represent the physiological confirmations of the residues in the context of the 3D protein structure.
- To analyze each identified residue in the context of the full-length H3L protein we mapped them onto the previously determined crystal structure of H3L. All but two residues (N40 and F135) mapped to the surface of the protein and therefore would potentially be available for interaction with the Abs. N40 and F 135 mapped on the inside folds of the protein and therefore would be unlikely to interact with the Abs.
- An additional residue P44 was identified by a separate experiment (see below) and therefore was also included in our design.
- a mutant H3L protein comprises the following mutations: I14A, D15A, R16A, K33A, F34A, D35A, K38A, N40A, E45A, V52A, E131A, T134A, F135A, L136A, R137A, R154A, E155A, I156A, K161A, L166A, V167A, M168A, I198A, R227A, E250A, K253A, P254A, N255A, and F256A.
- An example of mutant H3L amino acid sequence is shown in SEQ ID NO: 1.
- a DNA fragment containing the proteins’ native promoter, ORF (with mutations in place), and approximately ⁇ 250-bp flanking regions for homologous recombination into the appropriate gene in the VV genome was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- GFP green fluorescent protein
- the pUC57-Amp plasmids were transfected into the CV-1 cells and allowed to recombine with the VV genome.
- the fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination (HR) and GFP was removed using the LoxP sites.
- the correct gene insertion into the VV genome was verified by PCR.
- the plasmids were transfected into the CV-1 cells infected with the VV one at a time, starting with the LIR plasmid, following by A27L, D8L, and finally H3L. With the addition of each plasmid rounds of screening and purification were performed, followed by PCR and sequencing to make sure that the correct mutations were present.
- GFP was removed before the recombination with the next plasmid.
- the final variant contains modifications in all four proteins.
- Nucleotide substitutions in a synthesized H3L construct result in the following amino acid mutations: I14A, D15A, R16A, K38A, P44A, E45A, V52A, E131A, T134A, L136A, R137A, R154A, E155A, I156A, M168A, I198A, E250A, K253A, P254A, N255A, and F256A.
- the mutant H3L amino acid sequence is shown in SEQ ID NO: 11.
- Nucleotide sequences for such mutated H3L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 12.
- Nucleotide substitutions in a synthesized D8L construct result in the following amino acid mutations: R44A, K48A, K98A, K108A, K117A, and R220A.
- the mutant D8L amino acid sequence is shown in SEQ ID NO:2.
- Nucleotide sequences for such mutated D8L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 13.
- Nucleotide substitutions in a synthesized A27L construct result in the following amino acid mutations: K27A, A30D, R32A, E33A, A34D, I35A, V36A, K37A, D39A, E40A, R107A, P108A, and Y109A.
- the mutant A27L amino acid sequence is shown in SEQ ID NO:3.
- Nucleotide sequences for such mutated A27L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 14.
- Nucleotide substitutions in a synthesized L1R construct result in the following amino acid mutations: E25A, N27A, Q31A, T32A, K33A, D35A, S58A, D60A, D62A, K125A, and K127A.
- the mutant L1R amino acid sequence is shown in SEQ ID NO:4.
- Nucleotide sequences for such mutated L1R gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 15.
- Prior to infection virus was preincubated with Ab 9503-2057 (40 gg/mL) for 1 hr at 37°C. Samples were collected at 24, 48, and 72 hrs and titers were determined for each time point. The recombinant virus was significantly more efficient in replicating in the presence of Ab, compared to the control Ab, which was almost entirely inactivated.
- Fig 8 Anti-tumor efficiency of the recombinant virus was evaluated (Fig 8).
- Cells were incubated for 48 hrs and cell viability was measured by MTS assay (colorimetric assessment of cell metabolic activity). Briefly, cells collected at 48 hrs were washed once with PBST and resuspended at 1 c 105 cells/mL in complete DMEM. One hundred pL of each cell suspension was added to a 96-well (in triplicates).
- VV mutants that resisted the neutralization by ab35219 and ab21039 were selected. Briefly, a stock of mutant VV was prepared from CV-1 cells that were infected with the Western Reserve strain of VV in the presence of ethyl methanesulfonate (EMS) to induce transition mutations in viral DNA. Polyclonal anti-VV ab35219 and ab21039 were then used to neutralize the mutated virus. EMS was present in the culture medium at 500 pg/mL.
- EMS ethyl methanesulfonate
- the mutant viral stock was incubated with the mixture of two polyclonal Abs at 50 pg/ml each (100 pg/ml total cone.) for 1 hr, and then used to infect the CV-1 cells plated in the 12-well plates. After 2 hrs the inoculum was removed and fresh complete DMEM was added to the cells. Cells were then incubated at 37 °C, 5% CO2 for 48 hrs. During the first round of infection, the titer of the mutant virus was significantly reduced by the Abs. After a multiple rounds of infections with constant Ab concentration and with the increasingly more purified virus than the previous round, the passaged viral stock was no longer significantly neutralized by the Abs.
- VV EM escape mutant
- D8L coding sequence contains the following mutations: V43F/L, R44W, G55W, A144T, T168S, S177Y, F199Y, L203S, P212T, N218C, P222L, and D227G.
- the A27L coding sequence showed two mutations at residues 135 and D39 that were previously determined to be involved in the NAb interaction with A27L and were included in our A27L plasmid design.
- the H3L sequence showed an amino acid substitution at residue P44, a residue immediately adjacent to the E45 residue identified by the peptide array as part of the Ab- binding peptide (peptide 3; Fig. 2A) and thus was also included in the H3L recombinant plasmid design.
- SEQ ID NO: 5 shows a mutant H3L amino acid sequence.
- SEQ ID NO:6 or SEQ ID NO: 174 shows a mutant D8L amino acid sequence. Both SEQ ID NOs:6 and 174 were disclosed in parent application U.S. Provisional Patent Application No. 62/749,102 as SEQ ID NO:7.
- a new recombinant VV was made to incorporate the mutations that were identified as above.
- structural analysis of the proteins also identified additional residues that were not identified by either the peptide arrays or the EM sequencing but were adjacent to the residues that were identified and could potentially play a role in Ab interactions. Those residues were also included in the design.
- a DNA fragment containing the proteins’ native promoter, ORF (with mutations in place), and approximately ⁇ 250-bp flanking regions for homologous recombination into the appropriate gene in the VV genome was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
- a green fluorescent protein (GFP) expression cassette under the control of the VV p7.5 promoter and flanked by LoxP sites was inserted immediately downstream of the stop codon before the right flank sequence (Fig. 3).
- the fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination and GFP was removed using the LoxP sites.
- the pUC57-Amp plasmids were transfected into the CV-1 cells and allowed to recombine with the VV genome.
- the fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination (HR) and GFP was removed using the LoxP sites.
- the correct gene insertion into the VV genome was verified by PCR.
- the plasmids were transfected into the CV-1 cells infected with the VV one at a time, starting with the L1R plasmid, following by A27L, D8L, and finally H3L. With the addition of each plasmid rounds of screening and purification were performed, followed by PCR and sequencing to make sure that the correct mutations were present. GFP was removed before the recombination with the next plasmid.
- the final variant contains modifications in all four proteins.
- Nucleotide substitutions in a synthesized H3L construct result in the following amino acid mutations: I14A, D15A, R16A, K33A, F34A, D35A, K38A, N40A, P44A, E45A, V52A, E131A, D132A, T134A, F135A, L136A, R137A, R154A, E155A, I156A, K161A, L166A, VI 67 A, M168A, E195A, I198A, V199A, R227A, E250A, N251A, M252A, K253A, P254A, N255A, F256A, S258A, T262P, A264T, K266I, Y268C, M272K, Y273N, F275N, and T277A.
- the mutant H3L amino acid sequence is shown in SEQ ID NO: 170.
- Nucleotide sequences for such mutated H3L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 171.
- Nucleotide substitutions in a synthesized D8L construct result in the following amino acid mutations: V43A, R44A, K48A, S53A, G54A, G55A, K98A, K108A, K109A, A144G, T168A, S177A, L196A, F199A, L203A, N207A, P212A, N218A, R220A, P222A, andD227A.
- the mutant D8L amino acid sequence is shown in SEQ ID NO: 172.
- Nucleotide sequences for such mutated D8L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 173.
- Nucleotide substitutions in a synthesized A27L construct result in the following amino acid mutations: K27A, A30D, R32A, E33A, A34D, I35A, V36A, K37A, D39A, E40A, R107A, P108A, and Y109A.
- the mutant A27L amino acid sequence is shown in SEQ ID NO:3.
- Nucleotide sequences for such mutated A27L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 14.
- Nucleotide substitutions in a synthesized L1R construct result in the following amino acid mutations: E25A, N27A, Q31A, T32A, K33A, D35A, S58A, D60A, D62A, K125A, and K127A.
- the mutant L1R amino acid sequence is shown in SEQ ID NO:4.
- Nucleotide sequences for such mutated L1R gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 15.
- VV Expressing CD55 [0139] The oncolytic vaccinia virus (VV) construct CD55-NEV was generated to human CD55 extracellular domain. Human CD55 extracellular domain fused to VV A27 were optimized and synthesized and cloned into a pMS shuttle plasmid (Fig. 11). Vaccinia viruses (Western Reserve strain) expressing CD55-A27 were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV. The inserted CD55 and A27 was expressed under the transcriptional control of the original A27 promoter.
- the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of CD55, one of the corresponding clones was selected for amplification and purification.
- MOI multiplicity of infection
- an amino acid sequence comprising the CD55-A27 fusion is shown in SEQ ID NO:7.
- An example of an optimized nucleotide sequence for CD55-A27, containing signal peptide, CD55, A27 and linker sequence is shown in SEQ ID NO: 16.
- CD55-VV The ability of CD55-VV to escape complement-mediated neutralization was first investigated. To do this, CV-1 cells were seeded into 12-well plates and used within 2 days of reaching confluence. CD55-NEV or NEV control at 1 c 10 3 pfu/sample were added to the CV- 1 cells at 37°C / 5% CO2 in 300 pL of media in the presence of 1 : 10 human complement. Heat activated complement were used as control to calculate the escape rate. After 48 hrs, cells were fixed and stained with 1% crystal violet / 20% EtOH solution for 20 min at room temperature and plaques were counted. CD55-NEV escaped complement-mediated neutralization more effectively than NEV (Fig. 12). Around 59% of the CD55-NEV escaped complement- mediated neutralization, while only around 18% of NEV escaped complement-mediated neutralization.
- the oncolytic vaccinia virus (VV) construct FAP-TEA-NEV was generated to express a bispecific FAP-CD3 scFv targeting the FAP on cancer associated fibroblast (CAF) and CD3 on T cells.
- Bispecific FAP-CD3 scFv was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 14).
- the mhFAP -cross reactive single chain variable fragment (scFv M036) was previously generated by phage display from an immunized FAP/ knock-out mouse.
- Human CD3 scFv was derived from OKT3 clone.
- Vaccinia viruses (Western Reserve strain) expressing secretory bispecific FAP-CD3 scFv (FAP-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR VV or NEV.
- the inserted bispecific FAP-CD3 scFv was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation.
- BCMA-TEA-NEV the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of FAP-CD3, one of the corresponding clones was selected for amplification and purification.
- MOI multiplicity of infection
- an amino acid sequence comprising the FAP-CD3 polypeptide is shown in SEQ ID NO:8.
- An example of an optimized nucleotide sequence for the FAP-CD3 polypeptide, containing signal peptide, FAP scFv, CD3 scFv and linker sequence is shown in SEQ ID NO: 17.
- Fig.16 Flow analysis results suggested that FAP-TEA-VV induced U87 tumor apoptosis more effectively than NEV (Fig.16).
- Fig 17 showed the MFI of PI staining of gated U87 tumor cells.
- the oncolytic vaccinia virus (VV) construct BCMA-TEA-NEV was generated to express a bispecific BCMA-CD3 scFv targeting the BCMA on multiple myeloma and CD3 on T cells.
- Bispecific BCMA-CD3 scFv was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 19).
- BCMA scFV was derived from C11D5.3 clone (US9034324B2).
- Human CD3 scFv was derived from OKT3 clone.
- Vaccinia viruses (Western Reserve strain) expressing secretory bispecific BCMA-CD3 scFv (BCMA-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV.
- the inserted bispecific BCMA-CD3 scFv was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation.
- the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of BCMA-CD3, one of the corresponding clones was selected for amplification and purification.
- MOI multiplicity of infection
- an amino acid sequence comprising the BCMA-CD3 scFv is shown in SEQ ID NO: 9.
- An example of an optimized nucleotide sequence for the BCMA-CD3 scFv, containing signal peptide, BCMA scFv, CD3 scFv and linker sequence is shown in SEQ ID NO:18.
- the oncolytic vaccinia virus (VV) construct PD-l-ED-hlgGl-Fc-NEV was generated to express a recombinant protein with the extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl).
- FAP-CD3 is a bispecific molecule targeting the fibroblast activation protein on cancer associated fibroblast and CD3 on T cells.
- PD-l-ED- hlgGl-Fc was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 22).
- Vaccinia viruses (Western Reserve strain) expressing secretory PD-l-ED-hlgGl-Fc (PD-1- ED-hlgGl-Fc-NEV) or co-expressing secretory PD-l-ED-hlgGl-Fc and FAP-CD3 (PD-l-ED- hlgGl-Fc-FAP-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV. The inserted PD-l-ED- hlgGl-Fc was expressed under the transcriptional control of the pSE/L promoter.
- the inserted FAP-CD3 was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation.
- the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of PD-l-ED-hlgGl-Fc or FAP-CD3, one of the corresponding clones was selected for amplification and purification.
- an amino acid sequence comprising the PD-l-ED-hlgGl-Fc is shown in SEQ ID NO: 10.
- An example of an optimized nucleotide sequence for the PD-l-ED- hlgGl-Fc, containing signal peptide, PD-1 extracellular domain, human IgGl hinge and Fc domain is shown in SEQ ID NO: 19.
- CV-1 cells were infected with BCMA-TEA-NEV at MOI2 and the cell culture medium was collected after 24 hours and added to the co-culture of Raji and Jurkat T cells. After 6 hours of incubation, the supernatant was collected for luciferase measurement (Fig. 25). The results suggested secreted PD-l-ED-Fc effectively activated Jurkat T cells compared to control NEV or medium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention discloses recombinant vaccinia virus (VV) virions or oncolytic viruses that are resistant to antiviral defenses and have enhanced anti-tumor activities. In one embodiment, the recombinant VV comprise one or more variant VV proteins that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies. In another embodiment, the recombinant VV or oncolytic virus is resistant to complement-mediated neutralization due to the expression of a regulator of complement activation (e.g. CD55). In another embodiment, the recombinant VV or oncolytic virus has enhanced anti-tumor activities due to the expression of bi-specific antibodies co- targeting cancer cells and immune effector cells, or due to the expression of an immune checkpoint molecule (e.g. a polypeptide blocking the PD-1 pathway). These recombinant viruses can be used to treat cancer in a subject.
Description
MUTANT VACCINIA VIRUSES AND USE THEREOF
CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This Patent Cooperation Treaty Application claims the benefit of priority of U.S. Provisional Patent Application No. 62/912,344, filed on October 08, 2019, International Patent Application No. PCT/US2019/057134, filed on October 21, 2019, and U.S. Provisional Patent Application No. 62/942,306, filed on December 02, 2019.
BACKGROUND OF THE INVENTION
[0002] Oncolytic viruses specifically infect, replicate in, and kill tumor cells while leaving normal cells undamaged. This preference for the transformed cells pegs oncolytic viruses as ideal candidates for the development of new cancer therapies. Various oncolytic viruses have been utilized to employ their tumor-specific killing activities by both direct (e.g. cell lysis due to viral replication and immune-mediated cytotoxicity), and indirect mechanisms (e.g. stimulation of the bystander cell killing, induction of cytotoxicity, etc.). Oncolytic vaccinia virus (VV) is an appealing addition to the current treatment options, demonstrating efficacy and safety in animal models and in early clinical studies. In addition to infecting and killing tumor cells directly, VV may also induce a T-cell response against tumor antigens, increasing the efficiency of the killing. Whereas in some viruses this specificity toward cancer cells is naturally occurring (e.g. vesicular stomatitis virus, reovirus, mumps virus), other viruses can be genetically modified to improve their tumor specificity as well as to reduce their ability to induce antiviral immune response (e.g. adenovirus, measles virus, polio, and vaccinia virus). In addition, these viruses can be engineered to express genes that enhance antitumor immunity by recruitment of natural killer (NK) cells and T cells.
[0003] However, the effectiveness of oncolytic viruses is hindered by the strong immune response induced by the virus. Immune factors such as antibodies neutralize the virus by binding to it directly and preventing a successful infection of the cells or by marking it for destruction either by complement or by other immune cells. With each subsequent administration of the virus, the immune response is faster and stronger, which significantly
restricts the ability of the virus to persist long enough to reach the tumor. A direct injection of the virus into the tumor overcomes this limitation and delivers all the viral particles directly to the cancer cells. However, this approach may not be suitable for some tumors and does not take into the account cases in which the tumors may have metastasized to other locations. A more desirable systemic administration of the virus exposes it to the host immune system capable of recognizing and eliminating potential pathogens. Immune factors such as neutralizing antibodies (NAbs) recognize and bind viral glycoproteins with high affinity and prevent virus interaction with host cell receptors, leading to virus neutralization. Several oncolytic viruses, such as adenovirus, herpes simplex virus, and vesicular stomatitis virus, have been genetically attenuated to placate their ability to induce antiviral defenses and improve tumor specificity.
[0004] Oncolytic vaccinia virus (VV) is the most studied member of the Poxviridae and is a large, enveloped, dsDNA virus. Strains highly specific to the tumor cells have been reported. VV’s ability for rapid replication results in efficient lysis of infected cells as well as spread to other tumor cells upon successive rounds of replication, leading to profound localized destruction of the tumor. The VV genome encodes ~ 250 genes and can accept as much as 20 kb of foreign DNA, making it ideal as a gene delivery vehicle. The recombinant VV vectors are being developed to deliver eukaryotic genes, such as tumor-associated antigens, to the tumors and thus facilitate an induction of the host immune system directed to kill the cancer cells. However, a limiting factor in the use of VVs as cancer treatment delivery vectors is the strong NAb response induced by the injection of W into the bloodstream that limits the ability of the virus to persist and spread and prevents vector re-dosing. The NAbs recognize and bind viral glycoproteins embedded in the VV envelope, thus preventing virus interaction with host cell receptors. A number of VV glycoproteins involved in host cell receptor recognition have been identified. Among them, proteins H3L, L1R, A27L, D8L, A33R, and B5R have been shown to be targeted by NAbs, with A27L, H3L, D8L and L1R being the main NAb antigens presented on the surface of mature viral particles. A27L, H3L, and D8L are the adhesion molecules that bind to host glycosaminoglycans (GAGs) heparan sulfate (HS) (A27L and H3L) and chondroitin sulfate (CS) (D8L) and mediate endocytosis of the virus into the host cell. L1R protein is involved in virus maturation.
[0005] Vaccinia virus is the prototype virus of the orthopoxvirus genus in the family Poxviridae, which replicates in the cytoplasm of cells and encodes more than 200 open reading frames (ORFs) in a 190-kb double-stranded DNA genome. Vaccinia virus infection produces
multiple forms of infectious particles, namely, intracellular mature virions (IMV), intracellular enveloped virions (IEV), cell-associated enveloped virions (CEV), and extracellular enveloped virions (EEV). The IMV is the most abundant virion, with a single membrane in cells. IMVs are released only during cell lysis. Once released, IMVs efficiently infect neighboring cells via interactions between cell receptors and viral glycoproteins imbedded in the IMV membrane. A portion of the IMV is subsequently wrapped with two layers of Golgi membrane to form an IEV, which is transported through microtubules to the cell periphery and loses one membrane during virion egress to become a CEV. A small percentage (~ 5%) of the IMVs is moved toward the cell’s periphery where it acquires an outer envelope via fusion with the cell plasma membrane and is subsequently released into the extracellular space as an EEV. Thus, EEV is composed of the viral DNA core, the intermediate IMV, and an outermost membrane. This outer membrane is fragile and can be easily lost, thus EEVs are easily converted to the IMVs exposing the IMV imbedded antigens. The IMV is robust and is known to be resistant to environmental and physical changes, whereas the CEV and EEV are very fragile, and the integrity of their outer membranes can be destroyed during purification procedures.
[0006] Many of the poxvirus genomes, including those of different strains of vaccinia virus, have been sequenced. The genome of the vaccinia virus Western Reserve (WR) strain contains 218 potential ORFs. Analysis of the proteins in the IMV showed that it contains 81 viral proteins, including structural proteins, enzymes, transcription factors, etc. The 81 viral proteins in IMV are A2.5L, A3L, A4L, A5R, A6L, A7L, A9L, A10L, A12L, A13L, A14L, A14.5L, A15L, A16L, A17L, A18R, A21L, A22R, A24R, A25L, A26L, A27L, A28L, A29L, A30L, A31R, A32L, A42R, A45R, A46R, B1R, C6L, DIR, D2R, D6R, D7R, D8L, D11L, D12L, D13L, E1L, E4L, E6R, E8R, E10R, E11L, F8L, F9L, F10L, F17R, GIL, G3L, G4L, G5R, G5.5R, G7L, G9R, H1L, H2R, H3L, H4L, H5R, H6R, I1L, I2L, I3L, I5L, I6L, I7L, I8R, J1R, J3R, J4R, K4L, L1R, L3L, L4R, L5R, 02L. Among these proteins, A27L, H3L, L1R, and D8L have been identified as major immunogenic proteins. IMV proteins A27L, H3L, and D8L are the adhesion molecules that bind to host glycosaminoglycans (GAGs) heparan sulfate (HS) and chondroitin sulfate (CS) (D8L) and mediate endocytosis of the virus into the host cell. IMV L1R protein is involved in virus maturation. These proteins are the main immunodominant antigens on the IMV.
[0007] VV H3L is the membrane protein tethered to the membrane of the mature viral particles post-translationally via its hydrophobic region in the C-terminus. It is expressed late during the infection and, together with A27L, recognizes the HS cell surface receptors and plays a major role in VV adhesion to the cells. H3L is an immunodominant antigen in the anti-VV Ab response and a direct target of NAbs in humans immunized by the smallpox vaccine. Strong immune responses to H3L have also been shown in mice and rabbits. To date, the exact epitopes on H3L that are recognized by the NAbs have not been elucidated.
[0008] D8L is the VV envelope protein expressed early in infection and is involved in viral adhesion to host cells. While A27L and H3L interact with the HS host cell receptors, D8L binds to the CS receptors via its N-terminal domain (between residues 1-234). As one of the main viral antigens, D8L elicits a strong NAb response with the NAbs targeting the CS-binding region on the D8L and blocking viral adhesion to the cells. Several Abs targeting the D8L protein have been described. One of these Abs neutralized VV in the presence of a complement and targeted a conformational epitope on D8 (between residues 41 to 220). Residues R44, K48, K98, K108, and R220, a region adjacent to the CS binding site on D8L, are also important for Ab binding. In addition, N9, E30, T34, T35, N46, F47, K48, G49, G50, Y51, N59, E60, L63, S64, D75, Y76, H95, W96, N97, K99, Y101, S102, S103, Y104, E105, E106, K108, HI 10, D112, Q122, LI 24, D126, K163, T187, P188, and N190 have been identified as D8 antibody binding sites. It is not known whether mutation of these residues will confer sufficient escape from neutralization antibodies. Furthermore, whether mutations of these residues will impair virus packaging and cell entry due to D8L’s role in cell entry remain to be determined.
[0009] L1R is a transmembrane protein found on the surface of the mature VV particles. Its transmembrane domain lies in the C-terminal regions of the protein between residues 186 and 204. L1R is encoded by the L1R ORF, is highly conserved, and plays an essential role in viral entry and maturation. As one of the main targets of anti-VV NAb, L1R is included as a component of the poxvirus protein subunit and DNA vaccines. The NAb binding epitopes on the L1R protein have been characterized. An earlier study identified potent NAbs recognizing a linear epitope spanning residues 118-128 and a conformation epitope that partially overlapped with the linear peptide, specifically residues K125 and K127. A more recent study identified a group of 3 anti-LlR monoclonal Abs that potently neutralized VV in an isotype- and complement-independent manner. These NAbs recognized a conformational epitope with D35 as the key residue. Viral clones that contained a single amino acid mutation at residue D35
(either D35N or D35Y substitution) were completely resistant to neutralization by all Abs, indicating that D35 is essential for NAb recognition of L1R and binding. However, it is not clear if D35N will induce new neutralization antibody responses against 35N. In addition to D35, residues E25, N27, Q31, T32, K33, S58, D60, and D62 have been identified to be directly involved in binding with the Ab. It is not known whether mutations of these residues will escape neutralization antibody sufficiently and impair virus packaging and cell entry due to LIR’s role in cell entry.
[0010] A27L is a 14-kDa protein in the envelope of the intracellular mature virus (IMV) that functions in viral host cell recognition and entry. It binds to the HS receptor on the host cell surface via its N-terminal domain (residues 21 to 30) and is attached to the VV envelope by interacting with the envelope protein A17 through its C-terminal domain. A recent study has identified several linear epitopes on the A27L that are recognized by the anti-A27L Abs. The Abs were categorized into four different groups with the Abs in group I binding to the peptide (residues 31 to 40) adjacent to the HS binding site and showing potent virus neutralization in the presence of complement. Crystal structures of the full-length A27L in a complex with these Abs identified residues E33, 135, V36, K37, and D39 to be critical for binding. Alanine substitutions of these residues resulted in the decreased ability of the Abs to bind to the peptide. A further analysis of the structures showed that residues K27, A30, R32, A34, E40, R107, PI 08, and Y109, although not critical, also contribute to the A27L-Ab binding.
[0011] In view of the above, there is a need for improved or genetically attenuated vaccinia viruses that have reduced ability to induce antiviral defenses and have enhanced anti-tumor activities. For example, ways to reduce induction of antiviral defenses and enhance anti -turn or activities include strategies for resisting neutralizing antibodies, overcoming complement- mediated virus neutralization, arming vaccinia viruses with bi-specific polypeptides to boost virus therapy, and/or incorporating immune checkpoint molecules to boost virus therapy.
SUMMARY OF THE INVENTION
[0012] In one embodiment, the present invention provides mutant vaccinia viruses that are useful as viral vectors and vaccines.
[0013] In one embodiment, disclosed herein are recombinant vaccinia viruses comprising variant H3L, D8L, A27L and/or L1R viral proteins, including those of SEQ ID NOs:170 and
172. Further disclosed herein are recombinant vaccinia viruses comprising a heterologous nucleic acid encoding one of the following polypeptides: a domain of CD55 protein, a bi specific polypeptide that binds to CD3e and FAP (fibroblast activation protein), a bi-specific polypeptide that binds to CD3e and BCMA (B-cell maturation antigen), and a fusion polypeptide comprising human PD-1 extracellular domain.
[0014] In one embodiment, the present invention provides mutant vaccinia viruses and uses thereof. In one embodiment, there is provided mutant vaccinia viruses having one or more mutation in the genes encoding proteins involved in binding neutralization antibodies or T cells. These mutations result in mutant vaccinia viruses having the ability to escape vaccinia virus-specific neutralization antibodies or T cells when compared to the wild-type virus.
[0015] In one embodiment, the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, the recombinant VV virion comprises a heterologous nucleic acid and one or more of:
(a) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:l;
(b) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:2;
(c) a variant vaccinia virus (VV) A27L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:3;
(d) a variant vaccinia virus (VV) L1R protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:4;
(e) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:5;
(f) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 6 or SEQ ID NO: 174;
(g) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 170; and
(h) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 172.
[0016] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a nucleic acid encoding part or all of a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, and the like, and uses thereof. Expression of the complement activation modulators results in recombinant vaccinia viruses having the ability to modulate complement activation and reduce complement- mediated virus neutralization when compared to the wild-type virus. In one embodiment, the CD55 protein comprises the amino acid sequence of SEQ ID NO:7.
[0017] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a bi-specific FAP-CD3 scFv that comprises an amino acid sequence having the sequence of SEQ ID NO:8.
[0018] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a bi-specific BCMA-CD3 scFv that comprises an amino acid sequence having the sequence of SEQ ID NO:9.
[0019] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions or recombinant oncolytic viruses comprising a PD-l-ED-hlgGl-Fc fusion peptide that comprises an amino acid sequence having the sequence of SEQ ID NO: 10.
[0020] In another embodiment, the present invention provides a method of delivering a gene product to an individual in need thereof, the method comprising administering to the individual an effective amount of an infectious recombinant vaccinia virus (VV) virion or recombinant oncolytic viruses disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the recombinant virion.
[0021] In one embodiment, there is provided a pharmaceutical composition comprising the recombinant vaccinia virus (VV) virion or recombinant oncolytic viruses disclosed herein, and methods of using such composition to treat cancer.
[0022] In one embodiment, there is provided a library comprising one or more variant vaccinia virus (VV) virions, each of said variant VV virions comprises one or more variant VV protein, the variant VV protein comprises an amino acid sequence having at least one amino acid substitution relative to the amino acid sequence of a corresponding wild type VV protein.
[0023] In another embodiment, the present invention provides a method of delivering a gene product to an individual in need thereof, the method comprises administering to the individual an effective amount of infectious variant vaccinia virus (VV) virions derived from the above library, wherein the gene product is encoded by a nucleic acid carried by such variant VV virions.
[0024] In another embodiment, there is provided a pharmaceutical composition comprising variant vaccinia virus (VV) virions derived from the above library, and methods of using such composition to treat cancer.
[0025] In one embodiment, there is provided a recombinant vaccinia virus H3L protein that has at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to one of SEQ ID NOs:l, 5 or 170. In another embodiment, there is provided a recombinant vaccinia virus D8L protein that has at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NOs:6, 172 or 174.
BRIEF DESCRIPTION OF THE DRAWINGS [0026] Figures 1A-C show neutralizing antibody (Nab) epitope determination of H3L - peptide arrays sequence analysis. Antibody 35219 was used for binding to the peptide array of the H3L sequence (Ab35219 is a rabbit polyclonal to VV; Immunogen: Native virus, Lister strain).
[0027] Figure 1A shows diagram of the SPOT-synthesis peptide array. Figure IB shows autoradiograph of the H3L peptide array probed by ab35219. The peptide array consists of
spots of 12-residue peptides in the H3L sequence, starting from the N terminus (spot 1) and ending with the C-terminal peptide (spot 69), with the N-terminal residue of the peptide in each spot shifted by 4 residues from the previous spot along the H3L sequence. Figure 1C are graphs showing signal intensity (y axis) of each spot (black bars) (x axis).
[0028] Figures 2A-B show NAb epitope mapping of H3L by linear peptide ELISA. Figure 2A shows ELISA results for H3L peptides 1 - 4. Figure 2B shows ELISA results for H3L peptides 5 - 9. Arrows indicate some examples of alanine-substituted residues that have an effect on antibody (Ab) binding. Alanine scan identified total of 29 residues positive for Ab binding: I14A, D15A, R16A, K33A, F34A, D35A, K38A, N40A, E45A, V52A, E131A, T134A, F135A, L136A, R137A, R154A, E155A, I156A, K161A, L166A, V167A, M168A, I198A, R227A, E250A, K253A, P254A, N255A, and F256A. A lower optical density (OD) indicates that the alanine-substituted peptide preincubated with the Ab binds sufficiently to prevent the Ab binding to plate-bound native peptide. A higher OD (arrows) indicates the decreased ability of the mutant peptide to interact with the Ab, signifying that the mutated residue is important for H3L binding to Ab.
[0029] Figures 3A-D show construction of modified H3L, D8L, L1R, and A27L plasmids.
[0030] Figure 3A shows a construct containing the H3L promoter, H3L ORF (with mutated nucleotides), and approximately ~ 250-bp flanking regions containing the H4L (left flank) and the H2R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0031] Figure 3B shows a construct containing the D8L promoter, D8L ORF (with mutated nucleotides), and approximately ~ 250-bp flanking regions containing the D9R (left flank) and the D7R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0032] Figure 3C shows a construct containing the L1R promoter, L1R ORF (with mutated nucleotides), and approximately ~ 250-bp flanking regions containing the G9R (left flank) and the L2R (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0033] Figure 3D shows a construct containing the A27L promoter, A27L ORF (with mutated nucleotides), and approximately ~ 250-bp flanking regions containing the A28-A29L (left flank) and the A26L (right flank) ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid. For all four constructs a green fluorescent protein (GFP) expression cassette under the control of the VV p7.5 promoter and flanked by LoxP sites was inserted immediately downstream of the stop codon before the right flank sequence.
[0034] Figure 4 shows identification of the correct H3L, D8L, L1R, and A27L recombinant clones. Single plaques were purified and correct gene insertions were confirmed by PCR.
[0035] Figure 5 shows plaque reduction neutralization tests (PRNTs) using polyclonal anti- VV Abs. A panel of five anti-VV polyclonal antibodies consisting of ab35219 (Abeam) - rabbit polyclonal to VV (Immunogen: Native virus, Lister strain), ab21039 (Abeam) - rabbit polyclonal to VV (Immunogen: Lister Strain (mixture of virions and infected cell polypeptides)), ab26853 (Abeam) - rabbit polyclonal to VV (Immunogen: Synthetic peptide containing amino acids on the predicted N terminus of A27L in VV), 9503-2057 (Bio-Rad) - rabbit polyclonal against VV Ab (Immunogen: Vaccinia virus, New York City Board of Health (NYCBOH) strain), and PA1-7258 (Invitrogen) - rabbit polyclonal against VV (Immunogen: NYCBOH strain and Lister strain) was used to test for neutralization escape in vitro. Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the escape variant or the wt VV virus (control) in the presence of sterile baby rabbit complement. The mixture was then added to the CV-1 cells and 48 hrs later cells were stained and plaques counted. Whereas 83.3-95.5% of the control VV virus was neutralized across the panel, the escape variant (FAP-VVNEV) showed a significantly lower neutralization by the Abs (7.88- 66.1%). Error bars are based on two or three data points per sample.
[0036] Figure 6 shows VVEM (vaccinia virus escape mutant) in vitro plaque reduction neutralization test with anti-VV polyclonal Abs. VVEM was isolated from the mutant VV library pool in the presence of anti-VV polyclonal antibodies. A panel of five anti-VV polyclonal antibodies consisting of ab35219, ab21039, ab26853, 9503-2057, and PA1-7258 was used to test VVEMfor neutralization escape in vitro. Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the VVEM or the wild type VV virus (control) in the presence of sterile baby rabbit complement. Whereas 77.7-96.4% of the control VV virus was neutralized across the panel, VVEM showed a significantly lower (30.7-66.9%)
neutralization by the Abs. Error bars are based on two or three data points per sample. VVEM was further sequenced to identify the mutation within H3, LI, A27, or D8 that might be responsible for the Nab escape.
[0037] Figure 7 shows results of a recombinant virus replication assay. In a 24-well plate CV- 1 cells were infected with duplicates ofVV control and VYNEV atMOI = 0.05. Prior to infection virus was preincubated with Ab 9503-2057 (40 pg/mL) for 1 hour at 37°C. Samples were collected at 24, 48, and 72 hours and titers were determined for each time point. The recombinant virus was significantly more efficient in replicating in the presence of Ab, compared to the control Ab, which was almost entirely inactivated.
[0038] Figure 8 shows anti-tumor efficiency of the recombinant virus. The recombinant virus and the control VV were preincubated with Ab 9503-2057 (see above) and used to infect transformed cells at MOI=l . Cells were incubated for 48 hours and cell viability was measured by MTS assay (colorimetric assessment of cell metabolic activity). Briefly, cells collected at 48 hours were washed once with PBST and resuspended at 1 c 105 cells/mL in complete DMEM. One hundred pL of each cell suspension was added to a 96-well (in triplicates). Twenty pi of CellTiter 96® AQueous One Solution Reagent (Promega, G358C) was added into each well of the 96-well assay plate containing the samples in lOOpl of culture medium. The plate was incubated at 37°C for 2 hours (5% C02). To measure the amount of soluble formazan produced by cellular reduction of MTS, the absorbance in each well was recorded at 490nm using a 96-well plate reader. In the presence of the Ab, the recombinant virus was able to efficiently kill the cells.
[0039] Figure 9 shows a recombinant WNEV in vitro plaque reduction neutralization test with anti-VV polyclonal Abs. Anti-VV polyclonal antibodies 9503-2057 and PA1-7258 were used to test VVEM for neutralization escape in vitro. Rabbit polyclonal IgG ab37415 served as a control. Abs were preincubated with either the WNEV (right panel) or the wild type vaccinia virus (control, left panel) in the presence of sterile baby rabbit complement.
[0040] Figure 10 shows results of a recombinant virus replication assay. In a 24-well plate CV-1 cells were infected with duplicates of VV control and 3 single clones of VVNEV at MOI = 0.05. Samples were collected at 24, 48, and 72 hours and titers were determined for each time point.
[0041] Figure 11 shows a CD55-A27-VV construct containing the A27 promoter, CD55-ED, A27, loxP -flanked tag, and flanking regions containing the A27L (left flank) and the A27R (right flank). ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0042] Figure 12 shows CD55-NEV escapes complement-mediated neutralization effectively in vitro.
[0043] Figure 13 shows CD55-NEV escapes neutralization antibody and complement- mediated neutralization effectively in vitro.
[0044] Figure 14 shows aFAP-TEA-NEV construct containing the F17R promoter, FAP-CD3 scFv, loxP -flanked tag, and flanking regions containing the TKL (left flank) and the TKR (right flank). ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0045] Figure 15 shows a FAP-TEA-NEV enhanced tumor lysis and human T cell proliferation in vitro (see circle, microscopy observation).
[0046] Figure 16 shows a FAP-TEA-NEV induced tumor cell apoptosis effectively (flow cytometry analysis).
[0047] Figure 17 shows MFI of apoptosis marker PI staining of gated U87 tumor cells.
[0048] Figure 18 shows a bispecific FAP-CD3 scFv expressed by FAP-TEA-NEV enhanced bystander tumor lysis in vitro (see circles, microscopy observation).
[0049] Figure 19 shows a BCMA-TEA-NEV construct containing the F 17 promoter, BCMA- CD3 scFv, loxP -flanked GFP-tag, and flanking regions containing the TKL (left flank) and the TKR (right flank). ORF sequences was synthesized by GENEWIZ and cloned into the pUC57- Amp plasmid.
[0050] Figures 20A-B show flow cytometric analysis of co-culture of BCMA-positive RMPI- 8226 MM and Jurkat T cells.
[0051] Figures 21A-B show ELISA measurement of IFNy and IL2 expression by Jurkat T cells following 24 hours co-culture with BCMA-positive RMPI-8226 MM.
[0052] Figure 22 shows a PD-l-ED-hlgGl-Fc-VV construct containing the pE/L promoter, PD-l-ED-hlgGl-Fc, loxP -flanked GFP-tag, and flanking regions containing the TKL (left flank) and the TKR (right flank). A PD-l-ED-hlgGl-Fc-FAP-TEA-NEV construct containing the pE/L promoter, PD-l-ED-hlgGl-Fc, F17R promoter, FAP-CD3 scFv, loxP -flanked GFP- tag, and flanking regions containing the TKL (left flank) and the TKR (right flank) is also shown. ORF sequences was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid.
[0053] Figures 23A-B show flow cytometric analysis of co-culture of PD-L1 -positive Raji cells and CD 16-positive Jurkat T cells.
[0054] Figure 24A-B show ELISA measurement of IFNy and IL2 expression by CD 16- positive Jurkat T cells following 24 hours co-culture with PD-L1 -positive Raji cells.
[0055] Figure 25 shows the luciferase activity measurement of CD 16-positive Jurkat T cells following 24 hours co-culture with PD-L1 -positive Raji cells.
DETAILED DESCRIPTION OF THE INVENTION [0056] The present invention discloses the making and uses of variant vaccinia virus (VV) virions that have reduced ability to induce antiviral defenses and have enhanced anti-tumor activities. In another embodiment, the present invention discloses the making and uses of recombinant oncolytic viruses that have reduced ability to induce antiviral defenses and have enhanced anti-tumor activities.
Enhancing Resistance to Neutralizing Antibodies
[0057] In one embodiment, the variant vaccinia virus (W) virions of the present invention have increased resistance to anti-VV neutralizing antibodies. For example, the variant vaccinia
virus virions of the present invention comprise one or more variant VV proteins (such as H3L protein, D8L protein, A27L protein, and L1R protein) that have mutations at one or more neutralizing antibody epitopes, thereby conferring viral escape from the neutralizing antibodies.
[0058] The present specification discloses experiments studying variant VV protein H3L. The same experimental setup can be used to study other vaccinia virus viral proteins such as D8L protein, A27L protein, L1R protein etc. To identify possible regions on the viral protein that interact with neutralizing antibodies, peptide arrays encompassing the full-length viral protein was synthesized and screened for peptides that bound the anti-VV neutralizing antibodies. Peptides thus identified were further examined to elucidate the neutralizing antibody epitopes. In one embodiment, variants of the peptides identified by the peptide array were synthesized with alanine substitutions, and the neutralizing antibody epitopes were mapped using a series of ELISA binding assays. Once the neutralizing antibody epitopes were identified, mutations that destroy these epitopes can be introduced into the VV genome by genetic engineering.
[0059] The present invention discloses a number of neutralizing antibody epitopes on each of the vaccinia virus H3L protein, D8L protein, A27L protein, and L1R protein. Mutating or substituting amino acid(s) at these neutralizing antibody epitopes would confer viral escape from the neutralizing antibodies. Similarly, deleting amino acid(s) at these neutralizing antibody epitopes is also expected to confer viral escape from the neutralizing antibodies. Hence, it is expected that deletion of one or more amino acids within the H3L, D28L, A27L, L1R viral protein, or deletion of the whole H3L, D28L, A27L, or L1R viral protein could also confer escape from neutralizing antibody binding. H3L deletion mutant variants have been reported, indicating the feasibility of generating one or more amino acid deletion or whole protein deletion virus mutants, even though the H3L deletion impaired the virus mutant’s infectivity and replication capability.
[0060] In one embodiment, the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, comprising a heterologous nucleic acid and one or more of: a) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:l;
b) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:2; c) a variant vaccinia virus (VV) A27L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:3; d) a variant vaccinia virus (VV) L1R protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:4; e) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:5; f) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO:6 or SEQ ID NO: 174; g) a variant vaccinia virus (VV) H3L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 170; and h) a variant vaccinia virus (VV) D8L protein that comprises an amino acid sequence having at least about 60%, 70%, 80%, 90%, or 95% amino acid sequence identity to SEQ ID NO: 172.
[0061] In one embodiment, the above variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34,
35, 38, 40, 44, 45, 52, 131, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 198, 227,
250, 253, 254, 255, and 256 of SEQ ID NO:l. Any suitable amino acids can be used in the substitutions. For example, variant peptides can be synthesized with substitutions.
[0062] In one embodiment, the above variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 44, 48, 98, 108, 117, and 220 of SEQ ID NO:2. Any suitable amino acids can be used in the substitutions. For example, variant peptides can be synthesized with substitutions.
[0063] In one embodiment, the above variant VV A27L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 27, 30, 32, 33, 34, 35, 36, 37, 39, 40, 107, 108, and 109 of SEQ ID NO:3. Any suitable amino acids can be used in the substitutions. For example, variant peptides can be synthesized with substitutions.
[0064] In one embodiment, the above variant VV L1R protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 25, 27, 31, 32, 33, 35, 58, 60, 62, 125, and 127 of SEQ ID NO:4. Any suitable amino acids can be used in the substitutions. For example, variant peptides can be synthesized with substitutions.
[0065] In one embodiment, the above variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34,
35, 38, 40, 44, 45, 52, 131, 132, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 195, 198, 199, 227, 250, 251, 252, 253, 254, 255, 256, 258, 262, 264, 266, 268, 272, 273, 275, and
277 of SEQ ID NO: 170. Any suitable amino acids can be used in the substitutions.
[0066] In one embodiment, the above variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 43, 44, 48, 53, 54, 55, 98, 108, 109, 144, 168, 177, 196, 199, 203, 207, 212, 218, 220, 222, and 227 of SEQ ID NO: 172. Any suitable amino acids can be used in the substitutions.
Overcoming Complement-Mediated Virus Neutralization
[0067] Complement is a key component of the innate immune system, targeting the virus for neutralization and clearance from the circulatory system. Complement could enhance neutralization antibody’s neutralizing efficacy, and antibody -mediated protective immunity induced by smallpox vaccination was largely decreased in vitro in the absence of complement, indicating the critical role of complement in the neutralization of vaccinia virus. Complement activation results in cleavage and activation of C3 and deposition of opsonic C3 fragments on surfaces. Subsequent cleavage of C5 leads to assembly of the membrane attack complex (C5b, 6, 7, 8, 9), which disrupts lipid bilayers.
[0068] Complement activation can be negatively regulated by several membrane regulator of complement activation (RCA). RCAs downregulate complement activation at different steps. First, CD35 (complement receptor 1) and CD55 (decay-accelerating factor) inhibit the
formation and accelerate the decay of C3 convertases (C3 -activating enzymes). Second, CD35 and CD46 (membrane cofactor protein) catabolizes C4b and C3b, inhibiting formation of the C3 convertases C4b2a and C3bBb. Third, CD59 prevents the formation of the membrane attack complex. Studies have shown that extracellular enveloped vaccinia virus (EEV) is resistant to complement because of incorporation of host RCA into its envelope. However, it is not known whether CD55 and/or other RCAs can be successfully expressed on the surface of the IMV of VV with the ability of overcoming complement-mediated neutralization, without affecting viral packaging and replication.
[0069] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions comprising a heterologous nucleic acid encoding a part or all of a complement activation modulator such as CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPINGl), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, or other identified complement activation modulators, and uses thereof. Expressing the complement activation modulators results in recombinant vaccinia viruses having the ability to modulate complement activation and reduce complement-mediated virus neutralization as compared to the wild-type virus. In one embodiment, the heterologous nucleic acid carried by the above recombinant vaccinia virus (VV) virion encodes a complement activation modulators or a fragment thereof. The complement activation modulator can be human CD55, CD59, CD46, CD35, factor H, C4- binding protein, Cl inhibitor (Cl-INH, SERPINGl), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), Ml protein, or other identified complement activation modulators. In another embodiment, the heterologous nucleic acid encodes a CD55 protein that comprises an amino acid sequence having the sequence of SEQ ID NO:7. In view of the disclosure presented herein, one of ordinary skill in the art would readily employ other complement activation modulators (e.g. CD59, CD46, CD35, factor H, C4-binding protein etc) in the recombinant vaccinia virus presented herein.
[0070] The above invention of overcoming complement-mediated virus neutralization is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding a polypeptide that confers to the viruses resistance to antiviral defenses or enhanced anti-tumor activities. Examples of oncolytic viruses include, but are not limited to, adenovirus, adeno-associated virus, alphavirus, coxsackievirus, echovirus, flavivirus,
maraba virus, measles virus, myxoma virus, herpes simplex virus (hsv), newcastle disease virus, parvovirus, picornavirus, poliovirus, poxvirus, reovirus, rhabdovirus, semliki forest virus, seneca valley virus, vaccinia virus, vesicular stomatitis virus, or hybrid viral vectors derived from the above oncolytic viruses. In one embodiment, the heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof. Examples of regulator of complement activation include, but are not limited to, CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI), S-protein (vitronectin), clusterin (SP-40), or Ml protein. Expressing the complement modulators results in oncolytic viruses having the ability to modulate complement activation and reducing complement-mediated virus neutralization as compared to the wild-type virus. In another embodiment, the heterologous nucleic acid encodes a CD55 protein that comprises an amino acid sequence having the sequence of SEQ ID NO:7.
Incorporating Bi-Specific Antibodies To Boost Virus Therapy
[0071] Oncolytic virus can be armed to express bi-specific antibodies that bind to a first antigen on immune cells and a second antigen on tumor cells. Examples of the first antigen on immune cells include, but are not limited to, CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D, and the like. Examples of the second antigen on tumor cells include, but are not limited to, EphA2, HER2, GD2, Glypican-3, 5T4, 8H9, avb6 integrin, B7-H3, B7-H6, BCMA, CADC, CA9, CD 19, CD20, CD22, kappa light chain, CD30, CD33, CD38, CD44, CD44v6, CD44v7 /8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, EGFRvl 11, EGP2, EGP40, EPCAM, ERBB3, ERBB4, ErbB3/4, FAP, FAR, FBP, fetal AchR, Folate Receptor a, GD2, GD3, HLA-AI MAGE Al, HLA-A2, ILl lRa, IL13Ra2, KDR, Lambda, Lewis-Y, MCSP, Mesothelin, Mucl, Mucl6, NCAM, NKG2D ligands, NY-ESO-1, PRAME, PSCA, PSC1, PSMA, RORI, SURVIVIN, TAG72, TEM1, TEM8, VEGRR2, carcinoembryonic antigen, HMW-MAA, VEGF receptors, and other exemplary antigens that are present within the extracellular matrix of tumors, such as oncofetal variants of fibronectin, tenascin, or necrotic regions of tumors.
Targeting B-Cell Maturation Antigen (BCMA1 To Treat Multiple Myeloma [0072] Multiple myeloma (MM) is a malignancy of clonal plasma cells derived from the B- lymphocyte lineage that is part of a spectrum of diseases ranging from monoclonal gammopathy of undetermined significance (MGUS) to plasma cell leukemia. It is the second most common hematological cancer in the United States with an estimated 32,110 newly
diagnosed cases and 12,960 deaths in 2019. MM currently accounts for 10% of hematological malignancies and 2.1% of all cancer-related deaths. Currently several treatments for MM are available, however no curative therapies have been defined and most patients will eventually relapse with a median survival of 3-5 years, regardless of treatment regimen or initial responses to treatment. Therapeutics with new mechanisms of action are therefore urgently needed to treat drug-resistant MM.
[0073] Oncolytic vaccinia virus (VV) emerged as a promising new class of agents with great potential for the treatment of MM. Live VV has been administered by WHO to over 200 million people to eradicate smallpox, giving VV an excellent history of safety in humans. While wild type VV has no tumor selectivity, double deletion of viral genes that are essential for viral replication in normal cells, such as thymidine kinase (TK) and vaccinia growth factor (VGF), have conferred a strict VV tumor specificity. Recent clinical trials of VV against solid tumors are reporting promising results. In vitro studies utilizing a strain double deleted for TK and VGF showed that MM cell lines are susceptible to killing by VV. In those studies, viral replication was observed in primary MM cells, but not in normal peripheral blood mononuclear cells (PBMCs). The double deleted strain also reduced tumor volume and increased survival in a mouse xenograft model of MM. In addition, recently a TK-deleted VV strain that overexpresses two anti-tumor factors, miR-34a and Smac (frequently dysregulated in MM) showed increased efficacy against MM both in vitro and in vivo when compared to treatment with the parental virus, VV-miR-34a, or VV-Smac individually. However, the efficacy of VV therapy in current clinical studies is not optimized, indicating the need of further improvement of VV therapy.
[0074] VV can express T-cell engager targeting or co-targeting MM antigens, such as BCMA, CD 19, CD26, CD38, CD44v6, CD56, CD138, CS1, EGFR, integrin beta7, KIRs, LIGHT/TNF SF 14, NKG2D, PD-1/PD-L1, SLAMF7, TACI, and TGIT. B-cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is a promising target for MM therapy because it is expressed at significantly higher levels in all patient MM cells but not in normal tissues, except in plasma cells (PC). In recent clinical studies BCMA-targeted chimeric antigen receptor (CAR) T-cells showed significant clinical activities in patients with relapsed and refractory multiple myeloma (RRMM) who have undergone at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent. Anti-BCMA Ab-drug conjugate (ADC) also has achieved
significant clinical responses in patients who failed at least three prior lines of therapy. Both BCMA-targeted CAR-T and ADC were granted breakthrough status for patients with RRMM by FDA in Nov 2017. As promising as these two therapies are there are several complicating factors for targeting BCMA. First, anti-BCMA treatment will potentially reduce the number of long-lived PCs and, since long-lived PCs play a critical role in maintaining humoral immunity, the impact of anti-BCMA therapy on immune function needs to be carefully and serially evaluated. Second, high serum levels of sBCMA, cleaved from BCMA by g-secretase have been detected in MM patients, especially in the setting of progressive disease. Thus, it is necessary to develop a therapeutic strategy to deliver the BCMA-targeted treatment directly to BCMA+ MM cells.
[0075] As described herein, the present invention provides recombinant vaccinia virus (VV), BCMA-TEA-NEV, that overcomes the limitations discussed above because the BCMA-CD3 BiTE expression will be limited within the MM surrounding area while escaping the BCMA+ PCs and sBCMA. TEA-NEV encodes bi-specific scFvs that directs T cells to recognize and kill tumor cells that are not infected with VV (by-stander killing), resulting in enhanced tumor lysis. In addition, the CD3-scFv promotes T-cell infiltration into tumors and their activation, and the cytokines they release upon activation create a pro-inflammatory micro-environment that inhibites tumor growth. In addition, the TEA-NEV induces local production of T-cell engager that allows for higher concentrations of T cells at the target site while reducing systemic side effects. Thus, arming oncolytic VV with bi-specific scFvs is important to engage T cells for cancer therapy and produce the desired increase in anti-tumor activity of current VV by inducing by-stander killing.
[0076] In one embodiment, the heterologous nucleic acid carried by the above recombinant vaccinia virus (VV) virion encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen, B-cell maturation antigen (BCMA), on multiple myeloma (MM). For example, the bi-specific polypeptide is abi-specific scFvs, the first antigen is human CD3e, the second antigen is human BCMA (B-cell maturation antigen). In one embodiment, such bi-specific scFvs comprises an amino acid sequence of SEQ ID NO:9.
[0077] In another embodiment, VV can express T-cell engager targeting or co-targeting other MM antigens, such as CD 19, CD38, SLAMF7, CD26, LIGHT/TNFSF14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
[0078] In another embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP (fibroblast activation protein) that is overexpressed on most epithelial cancers. In one embodiment, the bi-specific FAP-CD3 scFv comprises the amino acid sequence of SEQ ID NO:8.
[0079] The above invention of incorporating bi-specific antibodies to boost virus therapy is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. Examples of oncolytic viruses have been discussed above. In one embodiment, the bi-specific polypeptide encoded by the heterologous nucleic acid is a bi-specific scFvs, the first antigen is human CD3e, the second antigen is human BCMA (B-cell maturation antigen). In one embodiment, such BCMA-CD3 scFv comprises an amino acid sequence of SEQ ID NO:9. In another embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP (fibroblast activation protein) that is overexpressed on most epithelial cancers. In one embodiment, the bi-specific FAP-CD3 scFv comprises the amino acid sequence of SEQ ID NO:8.
Incorporating Immune Checkpoint Molecules To Boost Virus Therapy [0080] Increasing evidence has shown that T-cell immunotherapy has the ability to control tumor growth and prolong survival in cancer patients. However, tumor-specific T-cell responses are hard to achieve and sustain, likely due to the limitations of various immune escape mechanisms of tumor cells. Immune checkpoint molecules are proteins expressed on certain immune cells that need to be activated or inhibited to start an immune response, for example, to attack abnormal cells such as tumor cells in the body. The “immune escape” may include several activities by the tumor cells, such as down-regulation of co-stimulatory molecule expression, such as stimulatory immune checkpoint molecules, and up-regulation of inhibitory molecule expression, such as inhibitory immune checkpoint molecules. Blockade of these inhibitory immune checkpoint molecules have shown very promising results in preclinical and clinical tests in cancer treatment. However, there are some unwanted side effects in some cases. For example, blocking these inhibitory immune checkpoint molecules
(receptors or ligands) may lead to a disruption in immune homeostasis and self-tolerance, resulting in autoimmune/auto-inflammatory side effects.
[0081] Immune checkpoint molecules are well-known in the art. For example, the PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are commonly expressed on the surface of dendritic cells or tumor cells. PD-1 and PD-L1/PD-L2 belong to the family of inhibitory immune checkpoint proteins that can halt or limit the development of T cell response. PD-L1 expressed on the tumor cells could bind to PD-1 receptors on the activated T cells, which leads to inhibition of cytotoxic T cells. Hence, anti-tumor immune responses would be enhanced by blocking the interaction between PD-1 and its ligands.
[0082] In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions that would block the inhibitory PD-1 pathway. In one embodiment, the present invention provides recombinant vaccinia virus (VV) virions comprising a heterologous nucleic acid encoding an extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl). In one embodiment, the PD-1 fusion protein (PD-l-ED-hlgGl-Fc) comprises the amino acid sequence of SEQ ID NO: 10. In view of the disclosure presented herein, other immune checkpoint molecules can be readily incorporated into the recombinant vaccinia virus presented herein. The recombinant vaccinia viruses disclosed herein may comprise immune checkpoint molecules including, but not limited to, PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
[0083] The above invention of incorporating immune checkpoint molecules to boost virus therapy is not limited to recombinant vaccinia virus. It can be applied to other oncolytic viruses. Accordingly, the present invention also provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding an immune checkpoint molecule. Examples of oncolytic viruses have been discussed above. In one embodiment, the present invention provides recombinant oncolytic viruses comprising a heterologous nucleic acid encoding an extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl). In one embodiment, the PD-1 fusion protein (PD-l-ED-hlgGl-Fc) comprises the amino acid sequence of SEQ ID NO: 10. In one embodiment, the recombinant oncolytic viruses disclosed herein may comprise immune checkpoint molecules including, but not limited to, PD-1, PD-
LI, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
[0084] In one embodiment, the present invention provides an isolated infectious recombinant vaccinia virus (VV) virion, the virion comprises a heterologous nucleic acid and one or more of: a) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 1; b) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 2; c) a variant vaccinia virus (VV) A27L protein having at least about 60% amino acid sequence identity to SEQ ID NO:3; d) a variant vaccinia virus (VV) L1R protein having at least about 60% amino acid sequence identity to SEQ ID NO: 4; e) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 5; f) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 6 or SEQ ID NO: 174; g) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 170; and h) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 172.
[0085] In one embodiment, the variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 198, 227, 250, 253, 254, 255, and 256 of SEQ ID NO: 1.
[0086] In one embodiment, the variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 44, 48, 98, 108, 117, and 220 of SEQ ID NO:2.
[0087] In one embodiment, the variant VV A27L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 27, 30, 32, 33, 34, 35, 36, 37, 39, 40, 107, 108, and 109 of SEQ ID NO:3.
[0088] In one embodiment, the variant VV L1R protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 25, 27, 31, 32, 33, 35, 58, 60, 62, 125, and 127 of SEQ ID NO:4.
[0089] In one embodiment, the variant VV H3L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 132, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 195, 198, 199, 227, 250, 251, 252, 253, 254, 255, 256, 258, 262, 264, 266, 268, 272, 273, 275, and 277 of SEQ ID NO: 170.
[0090] In one embodiment, the variant VV D8L protein comprises amino acid substitution or deletion at one or more of the following amino acid residues: 43, 44, 48, 53, 54, 55, 98, 108, 109, 144, 168, 177, 196, 199, 203, 207, 212, 218, 220, 222, and 227 of SEQ ID NO: 172.
[0091] In one embodiment, the heterologous nucleic acid carried by the recombinant VV encodes a regulator of complement activation or a fragment thereof. Examples of regulator of complement activation include, but are not limited to, CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), or Ml protein. In one embodiment, the heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
[0092] In another embodiment, the heterologous nucleic acid carried by the recombinant VV encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. In one embodiment, the first antigen on immune cells can be CD3, CD4, CD5, CD8, CD 16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, or NKG2D. In one embodiment, the second antigen on tumor cells can be fibroblast activation protein (FAP), or tumor antigens on multiple myeloma.
[0093] In one embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP. For example, this bi-specific polypeptide has the amino acid sequence of SEQ ID NO: 8.
[0094] In another embodiment, the bi-specific polypeptide can target tumor antigens on multiple myeloma, e.g. B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNF SF 14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, or CD44v6. In one embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human BCMA. For example, this bi-specific polypeptide has the amino acid sequence of SEQ ID NO:9.
[0095] In another embodiment, the heterologous nucleic acid carried by the recombinant VV encodes a fusion polypeptide comprising an immune checkpoint molecule. Examples of immune checkpoint molecule include, but are not limited to, PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD160, 2B4, and CD73. In one embodiment, the heterologous nucleic acid carried by the recombinant VV encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, e.g., this fusion polypeptide has the amino acid sequence of SEQ ID NO: 10.
[0096] In one embodiment, the recombinant vaccinia virus (VV) virion disclosed herein exhibits resistance to neutralizing antibodies compared to the resistance exhibited by wild type VV. In another embodiment, the recombinant vaccinia virus (VV) virion disclosed herein exhibits increased transduction of mammalian cells in the presence of anti-VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
[0097] In another embodiment, there is provided a method of delivering a gene product to a subject (human or animal) in need thereof. The method includes administering to the subject an effective amount of the recombinant vaccinia virus (VV) virion disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the recombinant VV virion.
[0098] In another embodiment, there is provided a pharmaceutical composition comprising the recombinant vaccinia virus (VV) virions disclosed herein and a pharmaceutically acceptable carrier. In another embodiment, there is provided a method of using such pharmaceutical
compositions to treat cancer in a subject. In one embodiment, the pharmaceutical compositions can be administered to the subject intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, enteral administration (e.g. through the gastrointestinal tract), or other systemic administration approach generally known in the art. In one embodiment, the subject is a human. Alternatively, the present invention may also be used in administration to and treatment of animal subjects.
[0099] In another embodiment, there is provided a library comprising one or more variant vaccinia virus (VV) virions, each of the variant W virions comprises one or more variant VV protein. The variant VV protein comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein. In one embodiment, the variant VV protein can be variant H3L protein, variant D8L protein, variant L1R protein, and/or variant A27L protein. In another embodiment, the variant VV protein comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence set forth in one of SEQ ID NOs:5, 6 or 174.
[0100] In another embodiment, there are provided variant vaccinia virus (VV) virions derived from the above library, the virions comprises a heterologous nucleic acid and one or more variant VV proteins, wherein at least one of the variant VV proteins comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein. In one embodiment, the heterologous nucleic acid carried by such variant VV virions encodes a regulator of complement activation or a fragment thereof. Examples of regulator of complement activation such as CD55 and others have been described above. In one embodiment, the heterologous nucleic acid encodes a CD55 protein that comprises the amino acid sequence of SEQ ID NO:7. In another embodiment, the heterologous nucleic acid encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. Examples of such first antigen and second antigen have been discussed above. In one embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human FAP, e.g. this bi-specific scFvs comprises the amino acid sequence of SEQ ID NO:8. In another embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e and the second antigen is human BCMA, e.g. this bi-specific scFvs comprises the amino acid sequence of SEQ ID NO: 9. In yet another embodiment, the heterologous nucleic
acid encodes a fusion polypeptide comprising an immune checkpoint molecule as discussed above. In one embodiment, the fusion polypeptide comprises human PD-1 extracellular domain and a human IgGl Fc domain, the fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
[0101] In one embodiment, the variant VV virions derived from the above library exhibit resistance to neutralizing antibodies compared to the resistance exhibited by wild type VV. In another embodiment, these variant VV virions exhibit increased transduction of mammalian cells in the presence of anti-VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
[0102] In another embodiment, there is provided a method of using an effective amount of recombinant vaccinia virus (VV) virions derived from the above library to deliver a gene product to a subject (human or animal) in need thereof, wherein the gene product is encoded by a nucleic acid carried by those variant VV virions.
[0103] In another embodiment, there is provided a pharmaceutical composition comprising variant vaccinia virus (VV) virions derived from the above library and a pharmaceutically acceptable carrier. In another embodiment, there is provided a method of using such pharmaceutical composition to treat cancer in a subject. In one embodiment, the pharmaceutical composition can be administered to the subject intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, enteral administration (e.g. through the gastrointestinal tract), or other systemic administration approach generally known in the art. In one embodiment, the subject is a human, but the technology may also be used in administration to and treatment of animal subjects.
[0104] In another embodiment, there is provided a recombinant vaccinia virus (VV) H3L protein that has at least about 60% amino acid sequence identity to one of SEQ ID NOs: 1, 5 or 170. In another embodiment, there is provided a recombinant vaccinia virus D8L protein that has at least about 60% amino acid sequence identity to one of SEQ ID NOs:2, 6, 172 or 174. These recombinant H3L or D8L proteins could confer viral resistance to anti-VV neutralizing antibodies.
[0105] The present invention also provides a recombinant oncolytic virus comprising a heterologous nucleic acid encoding a polypeptide that confers to said virus resistance to antiviral defenses or enhanced anti-tumor activities. Examples of oncolytic viruses include, but are not limited to, adenovirus, adeno-associated virus, alphavirus, coxsackievirus, echovirus, flavivirus, maraba virus, measles virus, myxoma virus, herpes simplex virus (HSV), newcastle disease virus, parvovirus, picornavirus, poliovirus, poxvirus, reovirus, rhabdovirus, Semliki Forest virus, Seneca Valley virus, vaccinia virus, vesicular stomatitis virus, and hybrid viral vectors thereof. In one embodiment, the heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof. Examples of regulators of complement activation include, but are not limited to,CD55, CD59, CD46, CD35, factor H, C4 -binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), and Ml protein. In one embodiment, the heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
[0106] In another embodiment, the recombinant oncolytic virus comprises a heterologous nucleic acid encoding a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells. Examples of first antigens on immune cells include, but are not limited to, CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D. Second antigens on immune cells can be fibroblast activation protein (FAP), or tumor antigens on multiple myeloma. Examples of tumor antigens on multiple myeloma include, but are not limited to, B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNFSF14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6. In one embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e, the second antigen is human FAP, and the bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO:8. In another embodiment, the bi-specific polypeptide is a bi-specific scFvs, the first antigen is human CD3e, the second antigen is human BCMA, and the bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO: 9.
[0107] In another embodiment, the recombinant oncolytic virus comprises a heterologous nucleic acid encoding a fusion polypeptide comprising an immune checkpoint molecule. Examples of immune checkpoint molecules include, but are not limited to, PD-1, PD-L1, PD- L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-
H4, CD 160, 2B4, and CD73. In one embodiment, the heterologous nucleic acid encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, and the fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
[0108] In one embodiment, the recombinant oncolytic virus disclosed herein exhibits resistance to neutralizing antibodies compared to that exhibited by wild type virus. In another embodiment, the recombinant oncolytic virus exhibits increased transduction of mammalian cells in the presence of neutralizing antibodies compared to transduction of mammalian cells by wild type virus.
[0109] In one embodiment, there is provided a method of delivering a gene product to an individual in need thereof, comprising administering to the individual an effective amount of the recombinant oncolytic virus disclosed herein, wherein the gene product is encoded by the heterologous nucleic acid carried by the oncolytic virus.
[0110] In one embodiment, the present invention provides a pharmaceutical composition comprising the recombinant oncolytic virus disclosed herein and a pharmaceutically acceptable carrier. In one embodiment, there is provided a method of using such pharmaceutical composition to treat cancer in a subject (e.g. a human or an animal). The pharmaceutical composition can be administered to the subject systemically, intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, or enteral administration.
[0111] The invention being generally described, will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
EXAMPLE 1
Materials And Methods
Materials
[0112] pUC57-Amp A27L, pUC57-Amp L1R, pUC57-Amp D8L, pUC57-Amp H3L, (GENEWIZ). CV-1 cells (ATCC, cat. # CCL-70). vSC20 Vaccinia virus stock. GeneJuice Transfection Reagent (Millipore, cat. # 2703870). DMEM media (GE Helathcare, cat. # SH30081.01), FBS (GE Healthcare, cat. # SH30070.03), DPBS (Sigma, cat. # 8537). Dry
ice/ethanol bath, 6-well tissue culture plates, 12 c 75-mm polystyrene tubes, disposable scraper or plunger from a 1 ml syringe, sterile 2-ml sterile microcentrifuge tubes.
Cell Preparation And Infection With Wild-Type Vaccinia Virus
[0113] CV-1 cells (2 c 105/well) were seeded in wells of a 6-well tissue culture plate in complete DMEM medium and incubate to 50-80% confluency (37 °C, 5% CO2 overnight). An aliquot of parental virus was thawed and sonicated (30 sec) in ice-water several times to remove the clumps (cool on ice between each sonication). Virus was diluted in complete DMEM to 0.5 x 105 pfu/ml. Medium was remove from confluent monolayer of cells and cells were infected with 0.5 ml diluted vaccinia virus (0.05 pfu/cell) and incubated 2 hrs at 37°C.
Transfection With pUC57-Amp Plasmid
[0114] For each well to be transfected, 100 mΐ serum-free medium was added into a sterile tube. Three mΐ GeneJuice was then added drop-wise directly to the serum-free medium and mixed thoroughly by vortexing and incubate at room temperature for 5 min. One pg of DNA was added to each tube and mixed by gentle pipetting (do not vortex) followed by incubation at room temperature for 5-15 min. Virus inoculum was then removed from monolayer of cells and washed twice with PBS. 0.5 mL of fresh complete DMEM medium was then added to the cells. The entire volume of GeneJuice/DNA mixture was then added drop-wise to cells in complete DMEM medium. The dish was gently rocked to ensure even distribution. Transfection mixture was removed after 4-8 hrs incubation and replaced with complete DMEM medium followed by incubation for 24-72 hrs at 37°C (5% C02). After 24-72 hours, the cells were dislodged from the wells and transferred to a 2-ml sterile microcentrifuge tube. The cell suspension was then lysed by performing three freeze-thaw cycles, each time by freezing in a dry ice/ethanol bath, thawing in a 37°C water bath, and vortexing. The cell lysate was stored at -80°C until needed
Screening of Recombinant Virus Plaques
[0115] CV1 cells (5 c 105/well) were seeded in a 6-well tissue culture plate in complete DMEM medium (2mL/well) and incubate to >90% confluency (37 °C, 5% CO2, 24 hrs). One hundred, 10, 1, or 0.1 mΐ of lysate were added to duplicate wells containing 1 ml complete DMEM medium and incubate 2 hrs at 37°C. The virus inoculum was then removed from the infected cells. 2 ml of complete DMEM medium containing 2.5% methylcellulose was added to each well with and incubated 2 days. Two days later, well-separated plaques were picked up by
scraping and suction with a pipet tip. Fluorescent microscope was used to select GFP+ plaques that was transferred to a tube containing 0.5 ml complete DMEM medium. Each virus- containing tube was vortexed followed by three freeze-thaw cycles, each time by freezing in a dry ice/ethanol bath, thawing in a 37°C water bath, and vortexing.
Several Rounds of GFP+ Plaque Purification
[0116] Wells of a 6-well tissue culture plate were seeded with 5 c 105 CV1 cells/well in complete DMEM medium (2mL/well). The cells were incubated to >90% confluency (37 °C, 5% CO2, 24 hrs). One 6-well plate is needed for each plaque isolate. One hundred, 10, 1, or 0.1 pi of lysate from each plaque were added to duplicate wells containing 1 ml complete DMEM medium, and incubated for 2 hrs. Medium was removed from the cell monolayers and overlay with complete DMEM containing 2.5% methylcellulose. The above steps were repeated for three or more rounds of plaque purification to ensure a clonally pure recombinant virus.
Single Plaque Purification Protocol
[0117] About 3-4 millions CV-1 cells were seeded and grown to 100% confluence in 24 well plate. The concentrated virus stock was diluted in 10-fold series dilutions with DMEM infection medium and added to each well. After 36-72 hour incubation, the wells that contain single plaque was marked and kept in the incubator until the whole well got infected, which takes about 4-5 days after initial infection. The infected cells were harvested and the recombination was confirmed by PCR assay. PCR conditions are listed below for each reaction.
EXAMPLE 2
Neutralizing Antibody (Nab) Epitope Determination on H3L - Peptide Arrays Sequence
Analysis
[0118] To identify possible regions on H3L that participate in the NAb interaction, peptide arrays encompassing full-length H3L were synthesized and screened for peptides that bound the anti-VV NAb. The array started at the N terminus of H3L and spanned the entire length of the protein sequence, with each successive spot containing 12 amino acids along the sequence shifted by 4 amino acids toward the C terminus, i.e., each spot in the array had an 8-residue overlap with the previous spot. Cellulose membrane containing synthesized H3L peptide array was then screened to identify peptides that bound to anti-VV polyclonal NAb (Abeam, ab35219). Briefly, the membrane was washed three times for 5 min in Millipore ThO and blocked overnight at 4°C with 5% (wt/vol) milk-PBS (MPBS). Four pg/mL NAb was incubated with the membrane in MPBS for 3 h at room temperature with gentle agitation. After incubation, membrane was washed six times for 5 min with 20 mL PBS supplemented with 1% Tween 20 (PBST). The peptide-bound NAb was detected by incubating the membrane with 2 pg/ml of rabbit horseradish peroxidase (HRP)-conjugated secondary Ab (Abeam, ab6721) in MPBS for 4 h at 4°C with gentle agitation. The membrane was then washed three times for 5 min with PBST, incubated in 5 ml of the enhanced chemiluminescence (ECL) developing solution (Thermo Fisher, #32109). Peptides that are positive for binding appear as spots on the membranes (Fig. IB). The signal was visualized, and the intensity of each spot was measured by a CCD camera (GE Healthcare, Amersham™ Imager 600). No over saturation of the spots was detected and after integrating, the intensities of the spots were plotted (Fig. 1C). A signal of < 110000 was considered background (determined by analysis of the membrane) and the spots showing a signal higher than 1100000 were considered to represent positive binding. Twenty six spots showed binding to ab35219 with higher than the cutoff intensity. To take into consideration that some positive signals could represent nonspecific binding, only those residues that were present in at least two spots that showed a binding intensity >1100000 were considered significant. In total 9 peptide sequences were identified positive for Ab binding
(sequences appeared in multiple spots with positive binding signal, sequences with underlines shown below).
TABLE 3
Sequences of The Spots (And Their Corresponding Positions') Synthesized Onto A Peptide
Sequences of The H3L Peptides (With Corresponding Residue Numbers') Identified By Peptide
Array
[0119] PVIDRLP (aa 11-18) (SEQ ID NO:89), NDQKFDDVKDN (aa 30-40) (SEQ ID NO:90), PERKNVVVV (aa 44-52) (SEQ ID NO:91), NVIEDITFLR (aa 128-137) (SEQ ID NO:92), QMREI (aa 152-156) (SEQ ID NO:93), KVKTELVM (aa 161-168) (SEQ IDNO:94), NIVDEIIK (aa 197-204) (SEQ ID NO: 95), KINRQI (aa 224-229) (SEQ ID NO: 96), FENMKPNF (aa 249-265) (SEQ ID NO:97).
[0120] Ab-binding sites localized to the N-terminal domain (aa 11 to 52), the central (aa 128 to 168) and the C-terminal portions (aa 198 to 256) of H3L. Interestingly, the most C-terminal domain of the protein (aa 260 to 324) showed no binding to the Ab. This hydrophobic region of the H3L inserts into VV membrane post-translationally and would not be available for Ab binding in the context of the mature viral particle. The N-terminal domain is most likely involved in the binding of H3L to surface of cells, thus binding of the Ab to this region would interfere with the ability of the virus to infect the cells, supporting our array result of this region being involved in Ab binding. Additionally, an earlier study showed that H3L is a glycosyltransferase. Some viruses encode their own glycosyltransferases to aid in host immune response evasion. H3L binds the UDP-Glc via the D/ExD motif in its central domain and mutating this motif (aa 125 and 127, specifically) inhibited the binding. The peptide array showed a likely Ab binding site near the D/ExD motif (peptide NVIEDITFLR, aa 128-137 (SEQ ID NO:92)). Binding of the Ab in this region would interfere with the glycosyltransferase activity of the H3L, another possible mechanism of virus neutralization by the Ab.
EXAMPLE 3
NAb Epitope Determination of H3L - Alanine Scan of The Identified Peptides [0121] To further map the NAb epitopes and to elucidate the key residues on the H3L peptides identified by our peptide array study, a series of ELIS As were performed with the 9 identified peptides and their alanine-substituted variants (Fig. 2). Variants of the 9 peptides identified by peptide array were synthesized with alanine substitutions (GenScript USA Inc. NJ, USA).
TABLE 4
[0122] The native peptides (non-mutated, shown above in bold, SEQ ID Nos: 89-97) were tagged with biotin (N-Terminal). 96-well Pierce™ NeutrAvidin coated plates (Thermo Fisher, 15507) were rinsed with PBST and incubated overnight at 4°C in the MPBS (blocking buffer, 100 pL/well). Blocking buffer was discarded, and 100 pL of biotinylated peptides was
added to the plate at 200 ng/mL and incubated for 90 min at 4°C. Simultaneously, anti-VV rabbit polyclonal NAb (Abeam, ab35219) was incubated with variant peptides. We used 30 pL/well of Ab at 800 ng/mL and incubated it with 30 pL/well of alanine-modified peptides at 100 pg/mL for 90 min at 4°C. After washing the plates with PBST, 50 pL of the Ab/alanine peptide mix was added to plate-bound peptides (in duplicate wells) and incubated for 60 min at 4°C. Plates were washed with PBST six times, and 100 pL/well of anti-rabbit horseradish peroxidase (HRP)-conjugated secondary Ab (Abeam, ab6721) diluted 1:1000 in MPBS was added. The plates were then incubated for 90 min at 4°C, washed with PBST four times and developed using 3,3’,5,5’,-Tetramethylbenzidine (TMB) (Sigma, T0440-100ML). The OD at 650 nm was read on Perkin Elmer Multimode Plate Reader (Corning). The intensity of each signal was measured and plotted using Kaleido™ 1.2 software. For each set of mutant peptides, a signal higher that the native control for that set was considered positive (Fig. 2). Control peptide for set 3 peptides (EKRNVVVV (SEQ ID NO: 169)) showed a signal higher than the rest of the peptides in the set with only two other peptides in this set showing a signal above 0.07. The scan identified a total of 29 residues positive for Ab binding: 114, D15, R16, K33, F34, D35, K38, N40, E45, V52, E131, T134, F135, L136, R137, R154, E155, 1156, K161, L166, VI 67, M168, 1198, R227, E250, K253, P254, N255, and F256 (Fig. 2). The peptide arrays involve linear peptides and therefore may not represent the physiological confirmations of the residues in the context of the 3D protein structure. To analyze each identified residue in the context of the full-length H3L protein we mapped them onto the previously determined crystal structure of H3L. All but two residues (N40 and F135) mapped to the surface of the protein and therefore would potentially be available for interaction with the Abs. N40 and F 135 mapped on the inside folds of the protein and therefore would be unlikely to interact with the Abs. An additional residue P44 was identified by a separate experiment (see below) and therefore was also included in our design. Lastly, the alanine scan identified 8 additional residues that showed a signal lower than the cutoff but higher than their respective controls, suggesting that they may also play a role in the Ab binding: K33, F34, D35, K161, L166, V167, and R227 (see Fig. 2).
[0123] In one embodiment, a mutant H3L protein comprises the following mutations: I14A, D15A, R16A, K33A, F34A, D35A, K38A, N40A, E45A, V52A, E131A, T134A, F135A, L136A, R137A, R154A, E155A, I156A, K161A, L166A, V167A, M168A, I198A, R227A, E250A, K253A, P254A, N255A, and F256A. An example of mutant H3L amino acid sequence is shown in SEQ ID NO: 1.
EXAMPLE 4
Homologous Recombination To Introduce Modified H3L. D8L. LIR. and A27L Genes
Into The VV Genome
[0124] For each modified protein a DNA fragment containing the proteins’ native promoter, ORF (with mutations in place), and approximately ~ 250-bp flanking regions for homologous recombination into the appropriate gene in the VV genome was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid. For all four constructs a green fluorescent protein (GFP) expression cassette under the control of the VV p7.5 promoter and flanked by LoxP sites was inserted immediately downstream of the stop codon before the right flank sequence (Fig. 3). The fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination and GFP was removed using the LoxP sites. The pUC57-Amp plasmids were transfected into the CV-1 cells and allowed to recombine with the VV genome. The fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination (HR) and GFP was removed using the LoxP sites. The correct gene insertion into the VV genome was verified by PCR.The plasmids were transfected into the CV-1 cells infected with the VV one at a time, starting with the LIR plasmid, following by A27L, D8L, and finally H3L. With the addition of each plasmid rounds of screening and purification were performed, followed by PCR and sequencing to make sure that the correct mutations were present. GFP was removed before the recombination with the next plasmid. The final variant contains modifications in all four proteins.
[0125] Nucleotide substitutions in a synthesized H3L construct result in the following amino acid mutations: I14A, D15A, R16A, K38A, P44A, E45A, V52A, E131A, T134A, L136A, R137A, R154A, E155A, I156A, M168A, I198A, E250A, K253A, P254A, N255A, and F256A. The mutant H3L amino acid sequence is shown in SEQ ID NO: 11. Nucleotide sequences for such mutated H3L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 12.
[0126] Nucleotide substitutions in a synthesized D8L construct result in the following amino acid mutations: R44A, K48A, K98A, K108A, K117A, and R220A. The mutant D8L amino acid sequence is shown in SEQ ID NO:2. Nucleotide sequences for such mutated D8L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 13.
[0127] Nucleotide substitutions in a synthesized A27L construct result in the following amino acid mutations: K27A, A30D, R32A, E33A, A34D, I35A, V36A, K37A, D39A, E40A, R107A, P108A, and Y109A. The mutant A27L amino acid sequence is shown in SEQ ID NO:3. Nucleotide sequences for such mutated A27L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 14.
[0128] Nucleotide substitutions in a synthesized L1R construct result in the following amino acid mutations: E25A, N27A, Q31A, T32A, K33A, D35A, S58A, D60A, D62A, K125A, and K127A. The mutant L1R amino acid sequence is shown in SEQ ID NO:4. Nucleotide sequences for such mutated L1R gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 15.
EXAMPLE 5
In vitro Neutralization Assays With Anti-VV Polyclonal Antibodies [0129] The ability of the anti-VV polyclonal Abs to neutralize the escape variants was investigated. A panel of anti-VV Abs consisting of ab35219 (Abeam), ab21039 (Abeam), ab26853 (Abeam), 9503-2057 (Bio-Rad), and PA1-7258 (Invitrogen) was used to test for neutralization escape in vitro. Rabbit polyclonal IgG ab37415 (Abeam) served as a control. CV-1 cells were seeded into 12-well plates and used within 2 days of reaching confluence. Forty pg/mL of Ab was preincubated with either the escape variant or the control VV at 1 x 103 pfu/sample for 1 hr at 37°C in the presence of 2% of sterile baby rabbit complement. The mixture was then added to the CV-1 cells and allowed to adhere for 2 hrs at 37°C / 5% CO2 in 300 pL of serum free media. After 2 hrs, the inoculum was removed and lmL of complete DMEM medium was added to the cells. The cells were then incubated at 37°C / 5% CO2. After 48 hrs cells were fixed and stained with 1% crystal violet / 20% EtOH solution for 20 min at room temperature and plaques were counted. All five Abs reduced the control VV plaque numbers dramatically, showing a strong neutralizing ability (Fig. 5). On average 83.3-95.5% of the control VV virus was neutralized across the panel. In contrast, the L1R+A27L+D8L+H3 escape variant showed a significantly lower neutralization by the Abs, with an average of 17.8 - 66.2% neutralization. Interestingly ab26853 neutralized 78% of control VV but almost completely failed to neutralize NEV variant (see Fig. 5). Based on these results, it is concluded that the escape variants disclosed herein can efficiently escape neutralization by anti-VV Abs in vitro.
[0130] Recombinant virus replication assay was performed (Fig 7). In a 24-well plate CV-1 cells were infected with duplicates of VV control, VVNEV, and VVEM at MOI = .05. Prior to infection virus was preincubated with Ab 9503-2057 (40 gg/mL) for 1 hr at 37°C. Samples were collected at 24, 48, and 72 hrs and titers were determined for each time point. The recombinant virus was significantly more efficient in replicating in the presence of Ab, compared to the control Ab, which was almost entirely inactivated.
[0131] Anti-tumor efficiency of the recombinant virus was evaluated (Fig 8). The recombinant virus and the control VV were preincubated with Ab 9503-2057 (see above) and used to infect transformed cells at MOI=l. Cells were incubated for 48 hrs and cell viability was measured by MTS assay (colorimetric assessment of cell metabolic activity). Briefly, cells collected at 48 hrs were washed once with PBST and resuspended at 1 c 105 cells/mL in complete DMEM. One hundred pL of each cell suspension was added to a 96-well (in triplicates). Twenty pi of CellTiter 96® AQueous One Solution Reagent (Promega, G358C) was added into each well of the 96-well assay plate containing the samples in lOOpl of culture medium. The plate was incubated at 37°C for 2 hrs (5% C02). To measure the amount of soluble formazan produced by cellular reduction of MTS, the absorbance in each well was recorded at 490nm using a 96- well plate reader. In the presence of the Ab, the recombinant virus was able to efficiently kill the cells.
EXAMPLE 6
[0132] To identify any additional key NAb epitope residues, VV mutants that resisted the neutralization by ab35219 and ab21039 were selected. Briefly, a stock of mutant VV was prepared from CV-1 cells that were infected with the Western Reserve strain of VV in the presence of ethyl methanesulfonate (EMS) to induce transition mutations in viral DNA. Polyclonal anti-VV ab35219 and ab21039 were then used to neutralize the mutated virus. EMS was present in the culture medium at 500 pg/mL. The mutant viral stock was incubated with the mixture of two polyclonal Abs at 50 pg/ml each (100 pg/ml total cone.) for 1 hr, and then used to infect the CV-1 cells plated in the 12-well plates. After 2 hrs the inoculum was removed and fresh complete DMEM was added to the cells. Cells were then incubated at 37 °C, 5% CO2 for 48 hrs. During the first round of infection, the titer of the mutant virus was significantly reduced by the Abs. After a multiple rounds of infections with constant Ab concentration and
with the increasingly more purified virus than the previous round, the passaged viral stock was no longer significantly neutralized by the Abs. A clone of the escape mutant (VVEM) was plaque purified and showed a significant escape of neutralization by a panel of five anti-VV Abs described above (Fig. 6). Whereas on average 77.7 - 96.4% of the control VV virus was neutralized across the panel, VVEM showed an average of 30.7 - 66.9% neutralization by the Abs, significantly lower than the control. Viral DNA from pure virus was isolated and PCR was used to amplify the A27L, L1R, H3L, and D8L genes, the major Ab antigens of the VV. PCR products were sequenced and showed presence of the mutations in the genes encoding A27L, D8L, and H3L. D8L coding sequence contains the following mutations: V43F/L, R44W, G55W, A144T, T168S, S177Y, F199Y, L203S, P212T, N218C, P222L, and D227G. The A27L coding sequence showed two mutations at residues 135 and D39 that were previously determined to be involved in the NAb interaction with A27L and were included in our A27L plasmid design. The H3L sequence showed an amino acid substitution at residue P44, a residue immediately adjacent to the E45 residue identified by the peptide array as part of the Ab- binding peptide (peptide 3; Fig. 2A) and thus was also included in the H3L recombinant plasmid design. Other mutations identified in the H3 gene are: E250G, N255W (these two residues were also identified by the alanine scan), S258F, T262P, A264T, T265V, K266I, Y268C, M272K, Y273N, F275N, and T277A. All of these mutations are clustered in the flexible C-terminal region of the protein. SEQ ID NO: 5 shows a mutant H3L amino acid sequence. SEQ ID NO:6 or SEQ ID NO: 174 shows a mutant D8L amino acid sequence. Both SEQ ID NOs:6 and 174 were disclosed in parent application U.S. Provisional Patent Application No. 62/749,102 as SEQ ID NO:7.
EXAMPLE 7
Homologous Recombination To Introduce Modified H3L. D8L. LIR. and A27L Genes
Into The VV Genome
[0133] A new recombinant VV was made to incorporate the mutations that were identified as above. In addition, structural analysis of the proteins also identified additional residues that were not identified by either the peptide arrays or the EM sequencing but were adjacent to the residues that were identified and could potentially play a role in Ab interactions. Those residues were also included in the design. For each modified protein a DNA fragment containing the proteins’ native promoter, ORF (with mutations in place), and approximately ~ 250-bp flanking regions for homologous recombination into the appropriate gene in the VV genome was synthesized by GENEWIZ and cloned into the pUC57-Amp plasmid. For all four constructs a
green fluorescent protein (GFP) expression cassette under the control of the VV p7.5 promoter and flanked by LoxP sites was inserted immediately downstream of the stop codon before the right flank sequence (Fig. 3). The fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination and GFP was removed using the LoxP sites. The pUC57-Amp plasmids were transfected into the CV-1 cells and allowed to recombine with the VV genome. The fluorescence marker expressed from the GFP cassette was used to screen for clones that had undergone homologous recombination (HR) and GFP was removed using the LoxP sites. The correct gene insertion into the VV genome was verified by PCR.The plasmids were transfected into the CV-1 cells infected with the VV one at a time, starting with the L1R plasmid, following by A27L, D8L, and finally H3L. With the addition of each plasmid rounds of screening and purification were performed, followed by PCR and sequencing to make sure that the correct mutations were present. GFP was removed before the recombination with the next plasmid. The final variant contains modifications in all four proteins.
[0134] Nucleotide substitutions in a synthesized H3L construct result in the following amino acid mutations: I14A, D15A, R16A, K33A, F34A, D35A, K38A, N40A, P44A, E45A, V52A, E131A, D132A, T134A, F135A, L136A, R137A, R154A, E155A, I156A, K161A, L166A, VI 67 A, M168A, E195A, I198A, V199A, R227A, E250A, N251A, M252A, K253A, P254A, N255A, F256A, S258A, T262P, A264T, K266I, Y268C, M272K, Y273N, F275N, and T277A. The mutant H3L amino acid sequence is shown in SEQ ID NO: 170. Nucleotide sequences for such mutated H3L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 171.
[0135] Nucleotide substitutions in a synthesized D8L construct result in the following amino acid mutations: V43A, R44A, K48A, S53A, G54A, G55A, K98A, K108A, K109A, A144G, T168A, S177A, L196A, F199A, L203A, N207A, P212A, N218A, R220A, P222A, andD227A. The mutant D8L amino acid sequence is shown in SEQ ID NO: 172. Nucleotide sequences for such mutated D8L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 173.
[0136] Nucleotide substitutions in a synthesized A27L construct result in the following amino acid mutations: K27A, A30D, R32A, E33A, A34D, I35A, V36A, K37A, D39A, E40A, R107A, P108A, and Y109A. The mutant A27L amino acid sequence is shown in SEQ ID NO:3.
Nucleotide sequences for such mutated A27L gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 14.
[0137] Nucleotide substitutions in a synthesized L1R construct result in the following amino acid mutations: E25A, N27A, Q31A, T32A, K33A, D35A, S58A, D60A, D62A, K125A, and K127A. The mutant L1R amino acid sequence is shown in SEQ ID NO:4. Nucleotide sequences for such mutated L1R gene, containing left flank region, promoter region, p7.5 promoter, LoxP, GFP, LoxP, and right flank regions are shown in SEQ ID NO: 15.
EXAMPLE 8
In vitro Neutralization Assays With Anti-VV Polyclonal Antibodies [0138] The ability of the anti-VV polyclonal Abs to neutralize the escape variants was investigated. Anti-VV Abs 9503-2057 (Bio-Rad) and PA1-7258 (Invitrogen) were used to test for neutralization escape in vitro. Rabbit polyclonal IgG ab37415 (Abeam) served as a control. CV-1 cells were seeded into 12-well plates and used within 2 days of reaching confluence. Forty gg/mL of Ab was preincubated with either the escape variant or the control VV at 1 x 103 pfu/sample for 1 hr at 37°C in the presence of 2% of sterile baby rabbit complement. The mixture was then added to the CV-1 cells and allowed to adhere for 2 hrs at 37°C / 5% CO2 in 300 pL of serum free media. After 2 hrs, the inoculum was removed and lmL of complete DMEM medium was added to the cells. The cells were then incubated at 37°C / 5% CO2. After 48 hrs cells were fixed and stained with 1% crystal violet / 20% EtOH solution for 20 min at room temperature and plaques were counted. NAbs reduced the control VV plaque numbers dramatically, showing a strong neutralizing ability (Fig. 9). On average 86.1-92.1% of the control VV virus was neutralized across the panel. In contrast, the escape variant showed a significantly lower neutralization by the Abs, with an average of 20.8 - 23% neutralization. Based on these results, it is concluded that the escape variants disclosed herein can efficiently escape neutralization by anti-VV Abs in vitro. The replication of the escape variant (3 single virus clones) and wild type VV were also compared in the absence of neutralization antibodies, the results suggested escape variants have similar replication capability compared to wild type virus, indicating that the mutation doeesn’t impair the virus’s entry and replication ability (Fig. 10).
EXAMPLE 9
Construction of VV Expressing CD55
[0139] The oncolytic vaccinia virus (VV) construct CD55-NEV was generated to human CD55 extracellular domain. Human CD55 extracellular domain fused to VV A27 were optimized and synthesized and cloned into a pMS shuttle plasmid (Fig. 11). Vaccinia viruses (Western Reserve strain) expressing CD55-A27 were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV. The inserted CD55 and A27 was expressed under the transcriptional control of the original A27 promoter. To construct the recombinant virus CD55-NEV, the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of CD55, one of the corresponding clones was selected for amplification and purification.
[0140] In one embodiment, an amino acid sequence comprising the CD55-A27 fusion is shown in SEQ ID NO:7. An example of an optimized nucleotide sequence for CD55-A27, containing signal peptide, CD55, A27 and linker sequence is shown in SEQ ID NO: 16.
EXAMPLE 10
In vitro Neutralization Assays With Complement or Complement/Anti-VV Polyclonal
Antibodies
[0141] The ability of CD55-VV to escape complement-mediated neutralization was first investigated. To do this, CV-1 cells were seeded into 12-well plates and used within 2 days of reaching confluence. CD55-NEV or NEV control at 1 c 103 pfu/sample were added to the CV- 1 cells at 37°C / 5% CO2 in 300 pL of media in the presence of 1 : 10 human complement. Heat activated complement were used as control to calculate the escape rate. After 48 hrs, cells were fixed and stained with 1% crystal violet / 20% EtOH solution for 20 min at room temperature and plaques were counted. CD55-NEV escaped complement-mediated neutralization more effectively than NEV (Fig. 12). Around 59% of the CD55-NEV escaped complement- mediated neutralization, while only around 18% of NEV escaped complement-mediated neutralization.
[0142] The ability of CD55-NEV to escape the neutralization of complement with anti-VV polyclonal Abs was further investigated. Two anti-VV Abs, 9503-2057 (Bio-Rad) and PA1- 7258 (Invitrogen), were used to test for neutralization escape in vitro. CV-1 cells were seeded into 12-well plates and used within 2 days of reaching confluence. Forty pg/mL of Ab was
preincubated with either CD55-NEV or the control VV at 1 x 103 pfu/sample for 1 hr at 37°C in the presence of 1 : 10 dilution of human complement. The mixture was then added to the CV-
1 cells and allowed to adhere for 2 hrs at 37°C / 5% CO2 in 300 pL of serum free media. After
2 hrs, the inoculum was removed and lmL of complete DMEM medium was added to the cells. The cells were then incubated at 37°C / 5% CO2. After 48 hrs cells were fixed and stained with 1% crystal violet / 20% EtOH solution for 20 min at room temperature and plaques were counted. The results suggested that CD55-NEV escaped the neutralization more effectively than NEV and VV in the absence or presence of complement (Fig. 13). Based on these results, it is concluded that the CD55-VV disclosed herein can efficiently escape complement/Nab mediated neutralization in vitro.
EXAMPLE 11
Construction of FAP-TEA-NEV
[0143] The oncolytic vaccinia virus (VV) construct FAP-TEA-NEV was generated to express a bispecific FAP-CD3 scFv targeting the FAP on cancer associated fibroblast (CAF) and CD3 on T cells. Bispecific FAP-CD3 scFv was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 14). The mhFAP -cross reactive single chain variable fragment (scFv M036) was previously generated by phage display from an immunized FAP/ knock-out mouse. Human CD3 scFv was derived from OKT3 clone. Vaccinia viruses (Western Reserve strain) expressing secretory bispecific FAP-CD3 scFv (FAP-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR VV or NEV. The inserted bispecific FAP-CD3 scFv was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation. To construct the recombinant virus BCMA-TEA-NEV, the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of FAP-CD3, one of the corresponding clones was selected for amplification and purification.
[0144] In one embodiment, an amino acid sequence comprising the FAP-CD3 polypeptide is shown in SEQ ID NO:8. An example of an optimized nucleotide sequence for the FAP-CD3 polypeptide, containing signal peptide, FAP scFv, CD3 scFv and linker sequence is shown in SEQ ID NO: 17.
EXAMPLE 12
Evaluation of FAP-TEA-NEV in vitro
[0145] Tumor lysis capacity of FAP-TEA-NEV was investigated. FAP -positive U87 tumor cells were seeded into 96-well plates at 5xl0e4 cell number per well. The U87 tumor cells were then infected with FAP-TEA-NEV or NEV at MOI 1, and co-cultured with human T cells at ration of U87:T = 1:5. After 48 hrs, cells were observed under microscope. The microscope picture showed that FAP-TEA-VV induced U87 tumor cell lysis and human T cell proliferation effectively compared to NEV (Fig.15). Cells were stained with apoptosis marker PI and Flow analysis results suggested that FAP-TEA-VV induced U87 tumor apoptosis more effectively than NEV (Fig.16). Fig 17 showed the MFI of PI staining of gated U87 tumor cells.
[0146] The ability of FAP-TEA-NEV to induce bystander tumor lysis was also investigated. CV-1 cells were infected with FAP-TEA-VV at MOI 1, and the cell culture medium were collected at 24 hours and added to co-culture of FAP -positive U87 tumor cells and human T cells at ratio of U87:T = 1:5. U87 tumor cells were seeded into 96-well plates at 5xl0e4 cell number per well. After 48 hrs, cells were observed under microscope. The microscope picture showed that FAP-TEA-VV induced U87 tumor cell lysis and human T cell proliferation effectively compared to NEV (Fig.18).
EXAMPLE 13
Construction of BCMA-TEA-NEV
[0147] The oncolytic vaccinia virus (VV) construct BCMA-TEA-NEV was generated to express a bispecific BCMA-CD3 scFv targeting the BCMA on multiple myeloma and CD3 on T cells. Bispecific BCMA-CD3 scFv was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 19). BCMA scFV was derived from C11D5.3 clone (US9034324B2). Human CD3 scFv was derived from OKT3 clone. Vaccinia viruses (Western Reserve strain) expressing secretory bispecific BCMA-CD3 scFv (BCMA-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV. The inserted bispecific BCMA-CD3 scFv was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation. To construct the recombinant virus BCMA-TEA-NEV, the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and
amplification to confirm the expression of BCMA-CD3, one of the corresponding clones was selected for amplification and purification.
[0148] In one embodiment, an amino acid sequence comprising the BCMA-CD3 scFv is shown in SEQ ID NO: 9. An example of an optimized nucleotide sequence for the BCMA-CD3 scFv, containing signal peptide, BCMA scFv, CD3 scFv and linker sequence is shown in SEQ ID NO:18.
EXAMPLE 14
Evaluation of BCMA-TEA-NEV in vitro
[0149] BCMA positive RPMI-8226 MM cell line was infected with BCMA-TEA-NEV or control NEV at MOI 2. After 24 hours, the virus infected RPMI-8226 cells were co-cultured with Jurkat T cells (Invivogen) at ratio of Jurkat T : RPMI-8226 = 2:1. After 24 hours of incubation, the cells were collected for counting the cell number and flow analysis of cell population. Flow analysis of the cell population suggested Jurkat T cells were significantly activated by BCMA-CD3 (Fig. 20A). Fig. 20B shows the cell number of the RPMI-8266 MM cells and activated Jurkat T cells. The results suggested that BCMA-TEA-NEV significantly induced Jurkat T cell activation and RPMI-8266 MM cell lysis compared to NEV control.
[0150] In the above experiment, after 24 hours of incubation, the cells were collected for measurement of cytokines IFNy (Fig. 21 A) and IL2 (Fig. 21B) secretion by ELISA. The results suggested that BCMA-TEA-NEV significantly induced IFNy and IL2 expression by Jurkat T cells compared to NEV control.
EXAMPLE 15
Construction of PD-l-ED-hlgGl-Fc-NEV
[0151] The oncolytic vaccinia virus (VV) construct PD-l-ED-hlgGl-Fc-NEV was generated to express a recombinant protein with the extracellular domain of PD-1 fused to the constant (Fc) domain of immunoglobin-Gl (IgGl). FAP-CD3 is a bispecific molecule targeting the fibroblast activation protein on cancer associated fibroblast and CD3 on T cells. PD-l-ED- hlgGl-Fc was optimized and synthesized and cloned into a pMS shuttle plasmid (FIG. 22). Vaccinia viruses (Western Reserve strain) expressing secretory PD-l-ED-hlgGl-Fc (PD-1- ED-hlgGl-Fc-NEV) or co-expressing secretory PD-l-ED-hlgGl-Fc and FAP-CD3 (PD-l-ED-
hlgGl-Fc-FAP-TEA-NEV) were generated by recombination of a version of pMS shuttle plasmid into the TK gene of the WR vaccinia virus (WR VV) or NEV. The inserted PD-l-ED- hlgGl-Fc was expressed under the transcriptional control of the pSE/L promoter. The inserted FAP-CD3 was expressed under the transcriptional control of the F17R late promoter to allow for sufficient viral replication before T-cell activation. To construct the recombinant virus PD- 1-ED-hIgGl-Fc-NEV or PD-l-ED-hlgGl-Fc-FAP-TEA-NEV, the shuttle vectors pMS were transfected into CV-1 or 293 cells. Cells were then infected with WR VV or NEV at a multiplicity of infection (MOI) of 0.1. After three rounds of plaque selection and amplification to confirm the expression of PD-l-ED-hlgGl-Fc or FAP-CD3, one of the corresponding clones was selected for amplification and purification.
[0152] In one embodiment, an amino acid sequence comprising the PD-l-ED-hlgGl-Fc is shown in SEQ ID NO: 10. An example of an optimized nucleotide sequence for the PD-l-ED- hlgGl-Fc, containing signal peptide, PD-1 extracellular domain, human IgGl hinge and Fc domain is shown in SEQ ID NO: 19.
EXAMPLE 16
Evaluation of PD1ED-NEV in vitro
[0153] Stable PD-Ll-Raji (Invivogen) cell line was infected with PD1ED-NEV or control NEV at MOI 2. After 24 hours, the virus infected PD-Ll-Raji cells were co-cultured with NFAT-CD16-Luc reporter Jurkat T cells (Invivogen) at ratio of Jurkat T : PD-Ll-Raji = 2:1. To investigate the role of the secreted PD-l-ED-Fc, CV-1 cells were infected with BCMA- TEA-NEV at MOI2 and the cell culture medium was collected after 24 hours and added to the co-culture of Raji and Jurkat T cells. After 24 hours of incubation, the cells were collected for flow analysis (Fig 23A) and counting (Fig 23B). The results suggested secreted PD-l-ED-Fc effectively induced Raji cell lysis compared to control group. PD-l-ED-Fc also induced significant Jurkat T cell exhaustion (Fig 19B). NEV infection of Raji has no effects likely because Raji is not susceptiable to VV infection. In the above experiment, after 24 hours of incubation, the cells were collected for measurement of cytokines IFNy (Fig. 24A) and IL2 (Fig. 24B) secretion by ELISA. The results suggested that secreted PD1ED significantly induced IFNy and IL2 expression by Jurkat T cells compared to NEV control.
[0154] In another experiment, stable PD-Ll-Raji (Invivogen) cell line was infected with PD1ED-NEV or control NEV at MOI 2. After 24 hours, the virus infected PD-Ll-Raji cells were co-cultured with NFAT-CD16-Luc reporter Jurkat T cells (Invivogen) at ratio of Jurkat T : PD-Ll-Raji = 2:1. To investigate the role of the secreted PD-l-ED-Fc, CV-1 cells were infected with BCMA-TEA-NEV at MOI2 and the cell culture medium was collected after 24 hours and added to the co-culture of Raji and Jurkat T cells. After 6 hours of incubation, the supernatant was collected for luciferase measurement (Fig. 25). The results suggested secreted PD-l-ED-Fc effectively activated Jurkat T cells compared to control NEV or medium.
Claims
1. An isolated infectious recombinant vaccinia virus (VV) virion, comprising a heterologous nucleic acid and one or more of: a) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 1; b) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO:2; c) a variant vaccinia virus (VV) A27L protein having at least about 60% amino acid sequence identity to SEQ ID NO:3; d) a variant vaccinia virus (VV) L1R protein having at least about 60% amino acid sequence identity to SEQ ID NO:4; e) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 5; f) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 6 or SEQ ID NO: 174; g) a variant vaccinia virus (VV) H3L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 170; and h) a variant vaccinia virus (VV) D8L protein having at least about 60% amino acid sequence identity to SEQ ID NO: 172.
2. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV H3L protein comprises amino acid substitution or deletion at one or more amino acid residues selected from the group consisting of 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 198, 227, 250, 253, 254, 255, and 256 of SEQ ID NO: 1.
3. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV D8L protein comprises amino acid substitution or deletion at one or more amino acid residues selected from the group consisting of 44, 48, 98, 108, 117, and 220 of SEQ ID NO:2.
4. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV A27L protein comprises amino acid substitution or deletion at one or more amino acid
residues selected from the group consisting of 27, 30, 32, 33, 34, 35, 36, 37, 39, 40, 107, 108, and 109 of SEQ ID NO:3.
5. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV L1R protein comprises amino acid substitution or deletion at one or more amino acid residues selected from the group consisting of 25, 27, 31, 32, 33, 35, 58, 60, 62, 125, and 127 of SEQ ID NO:4.
6. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV H3L protein comprises amino acid substitution or deletion at one or more amino acid residues selected from the group consisting of 14, 15, 16, 33, 34, 35, 38, 40, 44, 45, 52, 131, 132, 134, 135, 136, 137, 154, 155, 156, 161, 166, 167, 168, 195, 198, 199, 227, 250, 251, 252, 253, 254, 255, 256, 258, 262, 264, 266, 268, 272, 273, 275, and 277 of SEQ ID NO: 170.
7. The recombinant vaccinia virus (VV) virion of claim 1, wherein said variant VV D8L protein comprises amino acid substitution or deletion at one or more amino acid residues selected from the group consisting of 43, 44, 48, 53, 54, 55, 98, 108, 109, 144, 168, 177, 196, 199, 203, 207, 212, 218, 220, 222, and 227 of SEQ ID NO: 172.
8. The recombinant vaccinia virus (VV) virion of claim 1, wherein said heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof.
9. The recombinant vaccinia virus (VV) virion of claim 8, wherein said regulator of complement activation is selected from the group consisting of CD55, CD59, CD46, CD35, factor H, C4 -binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), and Ml protein.
10. The recombinant vaccinia virus (VV) virion of claim 1, wherein said heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
11. The recombinant vaccinia virus (VV) virion of claim 1, wherein said heterologous nucleic acid encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells.
12. The recombinant vaccinia virus (VV) virion of claim 11, wherein said first antigen on immune cells is selected from the group consisting of CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D.
13. The recombinant vaccinia virus (VV) virion of claim 11, wherein said second antigen on tumor cells is selected from the group consisting of fibroblast activation protein (FAP), and tumor antigens on multiple myeloma.
14. The recombinant vaccinia virus (VV) virion of claim 11, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human FAP, and said bi-specific polypeptide having the amino acid sequence of SEQ ID NO:8.
15. The recombinant vaccinia virus (VV) virion of claim 13, wherein the tumor antigens on multiple myeloma are selected from the group consisting of B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNF SF 14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
16. The recombinant vaccinia virus (VV) virion of claim 11, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human BCMA, and said bi-specific polypeptide having the amino acid sequence of SEQ ID NO:9.
17. The recombinant vaccinia virus (VV) virion of claim 1, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising an immune checkpoint molecule.
18. The recombinant vaccinia virus (VV) virion of claim 17, wherein said immune checkpoint molecule is selected from the group consisting of PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
19. The recombinant vaccinia virus (VV) virion of claim 1, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, said fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
20. The recombinant vaccinia virus (VV) virion of claim 1, wherein the VV exhibits resistance to neutralizing antibodies compared to that exhibited by wild type VV.
21. The recombinant vaccinia virus (VV) virion of claim 1, wherein the VV exhibits increased transduction of mammalian cells in the presence of VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
22. A method of delivering a gene product to a subject in need thereof, comprising administering to the subject an effective amount of the recombinant vaccinia virus (VV) virion of claim 1, said gene product is encoded by said heterologous nucleic acid.
23. A pharmaceutical composition comprising the recombinant vaccinia virus (VV) virion of claim 1 and a pharmaceutically acceptable carrier.
24. A method of treating cancer in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 23.
25. The method of claim 24, wherein the pharmaceutical composition is administered to the subject systemically, intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, or enteral administration.
26. The method of claim 24, wherein the subject is a human or an animal.
27. A library comprising one or more variant vaccinia virus (VV) virions, each of the one or more variant VV virions comprises one or more variant VV proteins, wherein at least one of said variant VV proteins comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein.
28. The library of claim 27, wherein at least one of the one or more variant VV proteins is selected from the group consisting of H3L protein, D8L protein, A27L protein, and L1R protein.
29. The library of claim 27, wherein at least one of the one or more variant VV proteins comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of one of SEQ ID No:5, SEQ ID No:6, or SEQ ID No: 174.
30. A recombinant vaccinia virus (VV) virion derived from the library of claim 27, comprising a heterologous nucleic acid and one or more variant VV proteins, wherein at least one of said variant VV proteins comprises an amino acid sequence having at least one amino acid substitution or deletion relative to the amino acid sequence of a corresponding wild type VV protein.
31. The recombinant vaccinia virus (VV) virion of claim 30, wherein said heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof.
32. The recombinant vaccinia virus (VV) virion of claim 31, wherein said regulator of complement activation is selected from the group consisting of CD55, CD59, CD46, CD35, factor H, C4-binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), and Ml protein.
33. The recombinant vaccinia virus (VV) virion of claim 31, wherein said heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
34. The recombinant vaccinia virus (VV) virion of claim 30, wherein said heterologous nucleic acid encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells.
35. The recombinant vaccinia virus (VV) virion of claim 34, wherein said first antigen on immune cells is selected from the group consisting of CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D.
36. The recombinant vaccinia virus (VV) virion of claim 34, wherein said second antigen on tumor cells is selected from the group consisting of fibroblast activation protein (FAP), and tumor antigens on multiple myeloma.
37. The recombinant vaccinia virus (VV) virion of claim 34, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human FAP, and said bi-specific polypeptide having the amino acid sequence of SEQ ID NO:8.
38. The recombinant vaccinia virus (VV) virion of claim 36, wherein the tumor antigens on multiple myeloma are selected from the group consisting of B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNF SF 14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
39. The recombinant vaccinia virus (VV) virion of claim 34, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human BCMA, and said bi-specific polypeptide having the amino acid sequence of SEQ ID NO:9.
40. The recombinant vaccinia virus (VV) virion of claim 30, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising an immune checkpoint molecule.
41. The recombinant vaccinia virus (VV) virion of claim 40, wherein said immune checkpoint molecule is selected from the group consisting of PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD 160, 2B4, and CD73.
42. The recombinant vaccinia virus (VV) virion of claim 40, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising human PD-1 extracellular
domain and a human IgGl Fc domain, said fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
43. The recombinant vaccinia virus (VV) virion of claim 30, wherein the VV virion exhibits resistance to neutralizing antibodies compared to wild type VV.
44. The recombinant vaccinia virus (VV) virion of claim 30, wherein the VV virion exhibits increased transduction of mammalian cells in the presence of VV neutralizing antibodies compared to transduction of mammalian cells by wild type VV.
45. A method of delivering a gene product to a subject in need thereof, comprising administering to the individual an effective amount of the recombinant vaccinia virus (VV) virion of claim 30, wherein the gene product is encoded by the heterologous nucleic acid carried by said variant VV virion.
46. A pharmaceutical composition comprising the recombinant vaccinia virus (VV) virion of claim 30 and a pharmaceutically acceptable carrier.
47. A method of treating cancer in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 46.
48. The method of claim 47, wherein the pharmaceutical composition is administered to the subject systemically, intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, or enteral administration.
49. The method of claim 47, wherein the subject is a human or an animal.
50. A recombinant vaccinia virus H3L protein having at least about 60% amino acid sequence identity to one of SEQ ID NOs:l, 5 or 170.
51. A recombinant vaccinia virus D8L protein having at least about 60% amino acid sequence identity to one of SEQ ID NOs:6, 172 or 174.
52. A recombinant oncolytic virus comprising a heterologous nucleic acid encoding a polypeptide that confers to said virus resistance to antiviral defenses or enhanced anti tumor activities.
53. The recombinant oncolytic virus of claim 52, wherein the oncolytic virus is selected from the group consisting of adenovirus, adeno-associated virus, alphavirus, coxsackievirus, echovirus, flavivirus, maraba virus, measles virus, myxoma virus, herpes simplex virus (HSV), newcastle disease virus, parvovirus, picornavirus, poliovirus, poxvirus, reovirus, rhabdovirus, Semliki Forest virus, Seneca Valley virus, vaccinia virus, vesicular stomatitis virus, and hybrid viral vectors thereof.
54. The recombinant oncolytic virus of claim 52, wherein said heterologous nucleic acid encodes a regulator of complement activation or a fragment thereof.
55. The recombinant oncolytic virus of claim 54, wherein said regulator of complement activation is selected from the group consisting of CD55, CD59, CD46, CD35, factor H, C4 -binding protein, Cl inhibitor (Cl-INH, SERPING1), CFH-related protein (CFHR-1), thrombomodulin, Factor 1 (CFI) , S-protein (vitronectin), clusterin (SP-40), and Ml protein.
56. The recombinant oncolytic virus of claim 55, wherein said heterologous nucleic acid encodes a CD55 polypeptide comprising the amino acid sequence of SEQ ID NO:7.
57. The recombinant oncolytic virus of claim 52, wherein said heterologous nucleic acid encodes a bi-specific polypeptide that binds to a first antigen on immune cells and a second antigen on tumor cells.
58. The recombinant oncolytic virus of claim 57, wherein said first antigen on immune cells is selected from the group consisting of CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD64, CD89, CD134, CD137, NKp46, and NKG2D.
59. The recombinant oncolytic virus of claim 57, wherein said second antigen on tumor cells is selected from the group consisting of fibroblast activation protein (FAP), and tumor antigens on multiple myeloma.
60. The recombinant oncolytic virus of claim 57, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human FAP, and said bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO:8.
61. The recombinant oncolytic virus of claim 59, wherein the tumor antigens on multiple myeloma are selected from the group consisting of B-cell maturation antigen (BCMA), CD 19, CD38, SLAMF7, CD26, LIGHT/TNFSF14, integrin beta7, CD138, KIRs, EGFR, PD-1/PD-L1, TGIT, CD56, CS1, NKG2D, TACI, and CD44v6.
62. The recombinant oncolytic virus of claim 57, wherein the bi-specific polypeptide is a bi-specific scFvs, said first antigen is human CD3e, said second antigen is human BCMA, and said bi-specific polypeptide comprises the amino acid sequence of SEQ ID NO:9.
63. The recombinant oncolytic virus of claim 52, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising an immune checkpoint molecule.
64. The recombinant oncolytic virus of claim 63, wherein said immune checkpoint molecule is selected from the group consisting of PD-1, PD-L1, PD-L2, CD47, CXCR4, CSF1R, LAG-3, TIM-3, HHLA2, BTLA, CTLA-4, TIGIT, VISTA, B7-H4, CD160, 2B4, and CD73.
65. The recombinant oncolytic virus of claim 52, wherein said heterologous nucleic acid encodes a fusion polypeptide comprising human PD-1 extracellular domain and a human IgGl Fc domain, said fusion polypeptide having the amino acid sequence of SEQ ID NO: 10.
66. The recombinant oncolytic virus of claim 52, wherein the virus exhibits resistance to neutralizing antibodies compared to that exhibited by wild type virus.
67. The recombinant oncolytic virus of claim 52, wherein the virus exhibits increased transduction of mammalian cells in the presence of neutralizing antibodies compared to transduction of mammalian cells by wild type virus.
68. A method of delivering a gene product to an individual in need thereof, comprising administering to the individual an effective amount of the recombinant oncolytic virus of claim 52, said gene product is encoded by said heterologous nucleic acid.
69. A pharmaceutical composition comprising the recombinant oncolytic virus of claim 52 and a pharmaceutically acceptable carrier.
70. A method of treating cancer in a subject, comprising administering to the subject an effective amount of the pharmaceutical composition of claim 69.
71. The method of claim 70, wherein the pharmaceutical composition is administered to the subject systemically, intravenously, or through injection, inhalant, infusion, implantation, parenteral administration, or enteral administration.
72. The method of claim 70, wherein the subject is a human or an animal.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962912344P | 2019-10-08 | 2019-10-08 | |
US62/912,344 | 2019-10-08 | ||
PCT/US2019/057134 WO2020086423A1 (en) | 2018-10-22 | 2019-10-21 | Mutant vaccinia viruses and use thereof |
USPCT/US2019/057134 | 2019-10-21 | ||
US201962942306P | 2019-12-02 | 2019-12-02 | |
US62/942,306 | 2019-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021071534A1 true WO2021071534A1 (en) | 2021-04-15 |
Family
ID=75437605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2019/065303 WO2021071534A1 (en) | 2019-10-08 | 2019-12-09 | Mutant vaccinia viruses and use thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021071534A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023118603A1 (en) * | 2021-12-24 | 2023-06-29 | Stratosvir Limited | Improved vaccinia virus vectors |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060062800A1 (en) * | 2003-02-28 | 2006-03-23 | The Trustees Of The University Of Pennsylvania & National Institute Of Health | Compositions, methods and kits relating to poxvirus subunit vaccines |
US20060222658A1 (en) * | 2004-12-01 | 2006-10-05 | David Roth | Vaccinia virus nucleic acids, polypeptides and immunogenic compositions |
US20090053256A1 (en) * | 2007-08-21 | 2009-02-26 | Shan Lu | Poxvirus Methods And Compositions |
US20130183271A1 (en) * | 2002-08-12 | 2013-07-18 | Jennerex, Inc. | Methods and Compositions Concerning Poxviruses and Cancer |
US20140186370A1 (en) * | 2007-10-10 | 2014-07-03 | La Jolla Institute For Allergy And Immunology | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
US20160355789A1 (en) * | 2013-06-21 | 2016-12-08 | The Johns Hopkins University | Virion display array for profiling functions and interactions of human membrane proteins |
US20160361439A1 (en) * | 2008-05-20 | 2016-12-15 | University Of Florida Research Foundation, Inc. | CAPSID-MUTATED rAAV VECTORS AND METHODS OF USE |
WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
-
2019
- 2019-12-09 WO PCT/US2019/065303 patent/WO2021071534A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130183271A1 (en) * | 2002-08-12 | 2013-07-18 | Jennerex, Inc. | Methods and Compositions Concerning Poxviruses and Cancer |
US20060062800A1 (en) * | 2003-02-28 | 2006-03-23 | The Trustees Of The University Of Pennsylvania & National Institute Of Health | Compositions, methods and kits relating to poxvirus subunit vaccines |
US20060222658A1 (en) * | 2004-12-01 | 2006-10-05 | David Roth | Vaccinia virus nucleic acids, polypeptides and immunogenic compositions |
US20090053256A1 (en) * | 2007-08-21 | 2009-02-26 | Shan Lu | Poxvirus Methods And Compositions |
US20140186370A1 (en) * | 2007-10-10 | 2014-07-03 | La Jolla Institute For Allergy And Immunology | Vaccinia virus h3l and b5r specific monoclonal antibodies and methods of making and using same |
US20160361439A1 (en) * | 2008-05-20 | 2016-12-15 | University Of Florida Research Foundation, Inc. | CAPSID-MUTATED rAAV VECTORS AND METHODS OF USE |
US20160355789A1 (en) * | 2013-06-21 | 2016-12-08 | The Johns Hopkins University | Virion display array for profiling functions and interactions of human membrane proteins |
WO2018049248A1 (en) * | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023118603A1 (en) * | 2021-12-24 | 2023-06-29 | Stratosvir Limited | Improved vaccinia virus vectors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210388388A1 (en) | Mutant vaccinia viruses and use thereof | |
JP7038664B2 (en) | Manipulated oncolytic virus | |
US7429481B2 (en) | Targeting viruses using a modified sindbis glycoprotein | |
JP6422134B2 (en) | Chimeric antigen receptor | |
JP5683455B2 (en) | Herpes simplex virus (HSV) with modified affinity, methods of use and preparation thereof | |
US20180305433A1 (en) | Cell | |
KR20180095511A (en) | Targeted Cancer Therapy | |
AU2018205763A1 (en) | Altered virus | |
US20200392535A1 (en) | Modified orthopoxvirus vectors | |
JP2020518613A (en) | Improved LAMP constructs containing cancer antigens | |
WO2021071534A1 (en) | Mutant vaccinia viruses and use thereof | |
JP7190166B2 (en) | Herpes virus with modified glycoprotein D | |
KR20210111237A (en) | Recombinant Herpes Simplex Virus Having Expression Cassette Expressing Fused Protein of Cancer Cell-Targeting Domain and Extracellular Damain of HVEM and Use Thereof | |
WO2019128996A1 (en) | Mesothelin-specific car-t cell expressing cd47 antibody, and use thereof | |
JP2022512595A (en) | Combination therapy to treat cancer by intravenous administration of recombinant MVA and immune checkpoint antagonists or immune checkpoint agonists | |
JP6025793B2 (en) | Herpes simplex virus (HSV) with modified affinity, methods of use and preparation thereof | |
CN116133671A (en) | Recombinant vaccinia virus | |
CN112759654A (en) | Virus envelope protein assembly system and method and application thereof | |
JP7456584B2 (en) | Tumor targeting proteins or fragments thereof, antibodies binding thereto and uses thereof | |
WO2020029274A1 (en) | Preparation method for attenuated baculovirus and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19948445 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19948445 Country of ref document: EP Kind code of ref document: A1 |